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Abstract
Pulmonary microvascular endothelial cell (PMVEC) interactions with the
extracellular matrix (ECM) mediates PMVEC barrier function. Further, data suggests an
association between decreased PMVEC-ECM interactions under proinflammatory conditions
and PMVEC barrier dysfunction. Tissue inhibitor of metalloproteinases 3 (TIMP3) may also
regulate barrier function, as PMVEC from Timp3-/- mice show increased leak. Studies in the
developing lung also showed TIMP3 regulating PMVEC-ECM interactions. Based on this, I
hypothesized that TIMP3 maintains PMVEC barrier function by promoting PMVEC-ECM
interactions.
Using the XperT-permeability assay, Timp3-/- PMVEC demonstrated enhanced leak
vs. WT PMVEC, particularly under proinflammatory conditions, and this was associated
with decreased phosphorylated focal adhesion kinase (pFAK). Furthermore, FAK inhibition
increased leak in WT PMVEC, and enhanced leak in Timp3-/- PMVEC under
proinflammatory conditions. Finally, MMP inhibition attenuated leak in Timp3-/- PMVEC
under both basal and proinflammatory conditions.
These results suggest a role for TIMP3 in mediating PMVEC-ECM interactions and
promoting PMVEC barrier function.
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Summary for Lay Audience
Endothelial cells (EC) line the blood vessels and are important in maintaining their
function. EC normally form a barrier by interacting with each other and with the supporting
scaffold found beneath the EC, known as extracellular matrix (ECM). A specific protein
called tissue inhibitors of metalloproteinases 3 (TIMP3) may help support EC in their role of
maintaining a barrier within the lungs as an absence of TIMP3 is shown to increase fluid
buildup in the lungs due to EC losing their ability to form a barrier. While exactly how
TIMP3 regulates EC in the lung is still unclear, it is possible that TIMP3 regulates the
interaction of EC with their environment. As such, I hypothesized that TIMP3 regulates lung
function by supporting the interaction of EC with the ECM.
By comparing normal mouse lung cells with cells that contained no TIMP3 (Timp3-/cells), I found that the Timp3-/- cells had fewer focal adhesion proteins in them, as compared
to the normal cells. Focal adhesions are important proteins found inside cells that help
maintain the interaction of cells with their environment. Additionally, the Timp3-/- cells
seemed to be leakier than the normal cells, as shown by a fluorescent protein that marked
where gaps would form between the cells and their environment. Addition of inhibitors that
targeted metalloproteinases, proteins that TIMP3 is shown to inhibit within the tissue,
rescued the increased leak in normal cells as well as in the Timp3-/- cells. Furthermore, after
adding inhibitors to block focal adhesion formation, both normal cells and Timp3-/- cells
showed an increase in leak. These results were especially prominent in groups where an
inflammatory environment was induced.
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These results show a promising start to understanding the role of TIMP3 in mediating
cellular interaction with each other and with the surrounding environment in the lungs.
Importantly, they suggest that TIMP3 and EC-ECM interactions may be a possible
therapeutic target for supporting the EC barrier function under inflammatory conditions in
the lungs.
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Chapter 1

1

Introduction

1.1 The vascular endothelium
The vascular system plays an important role in nutrient-provision and
waste removal from tissues and organ systems of the body 1. Additionally, it
regulates important homeostatic processes such as inflammation, barrier
maintenance, and wound repair 2. The vascular wall is made up of three distinct
layers: the tunica intima which directly interacts with blood, the tunica media
which alters vascular tone, and the tunica externa which provides structural and
other (i.e. nutritional, neurogenic) support to the vessels 1,3.
The tunica intima is comprised of the endothelium, a single-cell layer
composed of a heterogeneous population of endothelial cells (EC). While the
endothelium is present in blood and lymphatic vessels throughout the body, the
structure, function, and response of these cells differ depending on the type of
vessel, location and the stimulation they are exposed to 3. The endothelium can be
further segregated into macrovascular endothelial cells, which line large blood
vessels like the umbilical cord, and the microvascular endothelial cells (MVEC),
which line the capillaries and are regulators of tissue perfusion and
microcirculation 3–5. These vessels not only vary in size but also express
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heterogeneity in gene expression and functional processes like angiogenesis and
protein synthesis 3–5.
The endothelium is highly dynamic in its function, and its roles extend
beyond maintaining vessel structure and adequate circulation 6. For instance, the
EC form a tightly regulated, semi-permeable barrier, which controls the
movement of molecules and cells, allowing for compartmentalization within the
body 6. Furthermore, the EC secrete a variety of autocrine, paracrine, and
endocrine factors and also regulates vascular function through their interaction
with circulating compounds (i.e. hormones, neurotransmitters, and vasoactive
factors) 3,6. Through these interactions, EC are critical mediators of platelet and
leukocyte interactions, thrombosis and coagulation, regulating vascular tone, and
angiogenesis 7. Due to the extensive role of the endothelium in maintaining key
homeostatic processes, disruption of this layer is associated with numerous
pathologies, like atherosclerosis, chronic kidney disease, and sepsis 6.

1.2 Pulmonary microvasculature
The pulmonary endothelium differs widely in structure and function,
depending upon the location within the lungs. For instance, the pulmonary arterial
EC are situated on a thick membrane, whereas the capillary EC are separated from
sub-endothelial tissues only by a thin basement membrane 8. Additionally,
capillary EC express different lectin-binding proteins and cell adhesion molecules
compared to EC from larger pulmonary vessels 5. Not to mention, various stimuli
(i.e. bacterial insult, proinflammatory cytokines, etc.) result in varied responses
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amongst the different types of pulmonary endothelium, with diverse underlying
mechanisms mediating their response 5,8.
These site-specific differences are important for functional
compartmentalization within the lungs- for instance, the capillary EC form tight
barriers that mediate gas exchange and greatly limit the passage of fluid and
solutes between the blood and interstitial compartments of the lungs 5,8. Due to
these intrinsic differences in the endothelium throughout the lungs, capillary EC
and those of small arterioles and venules are often collectively referred to as
pulmonary microvascular EC (PMVEC).
PMVEC act as an interface between the circulating blood and the alveoli
of the lungs, making them critical in processes such as gas exchange, maintaining
barrier integrity, and regulating vascular tone through secretion of vasoactive
factors (i.e. nitric oxide, prostacyclin, endothelin) 9. These cells are highly
dynamic and depend on interactions with adjacent PMVEC, circulating factors
and cells, as well as signals from the surrounding extracellular matrix to maintain
a healthy, functional endothelium and blood vessel 9.

1.2.1 Endothelial barrier function
The ability of PMVEC to maintain a structurally functional barrier is key
for lung function. PMVEC form a semi-permeable monolayer that regulates the
efflux of fluid and molecules from the lumen into the pulmonary interstitial
compartment, allowing for adequate gas exchange 10.
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The EC barrier is regulated through cell-cell and cell-matrix interactions
10

. These interactions are modulated by numerous factors- for instance, the Rho

GTPases are shown to regulate EC barrier permeability by altering the formation
of actin stress fibers, interaction of intercellular junctional proteins, and focal
adhesion complexes (FAC).
There are multiple complexes that support inter-PMVEC adhesion,
specifically adherens junctions, tight junctions, and gap junctions 11,12. These
complexes are crucial in forming interactions between adjacent PMVEC to
maintain the intact endothelial monolayer 5. Tight junctions, formed through the
association of claudins with occludins, regulate the exchange of ions and solutes
between microvascular EC 11,12. Additionally, junctional adhesion molecules, a
family of transmembrane proteins, also contribute to the formation and
maintenance of tight junctions 12. However, the main regulators of inter-PMVEC
adhesion are the adherens junctions 11,13. These complexes are composed of a
specialized protein called vascular endothelial cadherin (VE-cadherin) that is
involved in cell stability, monolayer integrity, and cell signaling 11,13.
While PMVEC interact with adjacent PMVEC via junctional complexes,
they also interact with the underlying extracellular matrix (ECM) via integrins
11,14

. Integrin activation and binding to the ECM leads to the recruitment of

signaling proteins such as focal adhesion kinase (FAK) and the tyrosine kinase
Fyn, leading to the formation FAC 11,14. The establishment of FAC and the
interaction of PMVEC with the ECM further promotes endothelial barrier
function and regulation of microvascular permeability 11,15.
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The surrounding ECM, comprised largely of collagen, fibronectin, and
glycosaminoglycans (GAGs), adds to the restrictive property of the endothelium
required for normal tissue functioning 11,16. Collagen is the main structural
component of the ECM that helps regulate cell adhesion, cell migration, and
elasticity of the tissue by providing tensile strength 11,17,18. Heparan sulfate, one of
the most abundant GAGs, has numerous biological functions, including cell–
matrix interactions, chemokine activation, and regulation of degradative enzymes
11,16,19

. Fibronectin is important not only for the organization of ECM components

but also plays a role in cell adhesion and migration, and as a mechano-regulator
11,20,21

. These ECM components are intertwined in a complex network that

maintains the structural integrity of the matrix while allowing it to resist tensile
stresses and regulate movement of molecules under healthy conditions 11,16.
An intact endothelium, regulated through inter-PMVEC and cell-matrix
interactions, is crucial for maintaining functional blood-lung homeostasis. Healthy
EC interactions promote anti-thrombotic processes by limiting platelet and
leukocyte adhesion to the endothelial wall, and by deterring platelet activation and
aggregation 5. Additionally, resting PMVEC promote an anti-inflammatory
environment by limiting interaction with proinflammatory cytokines, mitigating
leukocyte extravasation into pulmonary tissue, and suppressing transcription of
adhesion and proinflammatory biomarkers 5. As such, any compromise to the
pulmonary endothelium results in EC dysfunction and impaired barrier regulation.
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1.2.2 Endothelial barrier dysfunction
Disruption of the pulmonary endothelium impairs the homeostatic balance
within the lungs, leading to a shift from an anti-inflammatory phenotype to an
activated proinflammatory phenotype 22. This causes acute inflammation within
the lung parenchyma through an accumulation of proinflammatory leukocytes and
platelets, activation of procoagulant pathways, and disruption of the PMVEC
barrier, ultimately resulting in pulmonary oedema and hypoxemia 22. This can
often result in acute lung injury (ALI) and if more severe, acute respiratory
distress syndrome (ARDS), which can be associated with multi-organ dysfunction
(MOD), and has a high risk of death 9.
PMVEC dysfunction is largely associated with proinflammatory
pathologies- the lung’s innate immune response recruits leukocytes to the
pulmonary microvasculature and promotes the extravasation of immune cells into
the alveolar space 9. This is mediated through the release of proinflammatory
markers (i.e. cytokines), which are initially secreted by activated leukocytes in the
circulation and within the pulmonary tissue 11. These cytokines direct leukocytePMVEC interaction, and stimulation of PMVEC with bacterial products (i.e.
lipopolysaccharides (LPS)) results in PMVEC activation and subsequent
dysfunction 11.
PMVEC activation leads to further downstream expression of PMVECdependent cytokines, cell surface leukocyte receptors (i.e. ICAM1 and VCAM1),
and of extracellular enzymes known to regulate inflammatory signaling pathways,
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such as the matrix metalloproteinases (MMPs) and closely related a disintegrin
and metalloproteinases (ADAMs) 11,23.
There are multiple mechanisms that can mediate the loss of PMVEC
barrier function under proinflammatory conditions. For instance, PMVEC
retraction due to actin cytoskeleton rearrangement and microtubule-dependent
PMVEC contraction is thought to promote gap formation and subsequent barrier
dysfunction 11,24. Additional mechanisms, such as enhanced transcytosis and
PMVEC apoptosis, may also play a role; however, the direct impact of these
mechanisms on the loss of PMVEC barrier function is unclear 11.
Loss of PMVEC intercellular junctions, including adherens and tight
junctions, has also been found to occur under proinflammatory conditions and is
thought to be a critical driver of PMVEC barrier dysfunction 11. The disruption of
PMVEC intercellular junctions is initiated by multiple mechanisms and is
characterized by the functional loss of key junctional proteins, such as VEcadherin 11,25. Loss of functional membrane VE-cadherin can be due to VEcadherin phosphorylation, targeted cleavage by extracellular proteases, including
MMPs and ADAMs, and loss of attachment to submembrane cytoplasmic adaptor
proteins (i.e. β-catenin), which link VE-cadherin to the actin cytoskeleton 13,24,25.
Moreover, it has been suggested that alterations to the basement
membrane leading to altered PMVEC–ECM interactions may also lead to
disruption of intercellular junctions and PMVEC barrier dysfunction 11. This may
be associated with focal adhesion kinase (FAK) activation, which promotes the
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assembly of FAC 22. FAC are shown to interact with integrin receptors on the cell
surface to promote PMVEC-ECM adhesion, and to help stabilize adherens
junctions to promote inter-PMVEC interactions 22. Meanwhile, activated FAK is
also a Rho-inhibitor, and its action may act to inhibit Rho-regulated barrier
dysfunction 22. The net effect of FAK activation could help regulate PMVEC
barrier stability and, subsequently, a lack thereof may be a critical mediator in
promoting barrier dysfunction.

1.3 Cellular interactions with the extracellular matrix (ECM)
The ECM is a meshwork of proteins secreted by cells that establishes a
micro-environment for the cells 26. It has numerous functions, from providing
structural support to mediating mechanical and biochemical signaling pathways
between cells 26. For instance, vascular development depends on the correct
interaction of the vascular progenitor cells with the surrounding basement
membrane and the underlying matrix proteins 27. While these interactions may
differ depending on the vessels and the microenvironment, in quiescent states, the
EC are non-proliferative and stably attached to the basement membrane 27.
Additionally, studies have shown that maintaining functional
differentiation of EC is dependent on providing them with an adequate
environment, part of which is the provision of a physiologically relevant basement
membrane, including specific components of the ECM 28.

9

Another role of an adequate environment is providing extracellular signals
that maintain the proper orientation of EC 29. In order to form and maintain a
functioning endothelium, EC have shown to secrete their own extracellular
matrix, which is deposited at the basal surface of these cells, allowing for
polarized adhesion 29. As such, cell-ECM interactions are critical in developing
and maintaining EC polarity and function 26,28,29.

1.3.1 Composition of the ECM
The vascular ECM is composed of a variety of proteins, including
laminins, collagens, fibronectin, and proteoglycans 30,31. During angiogenesis, the
secretion of specific biochemical molecules by the endothelium, including
transforming growth factor-β (TGFβ), stimulates ECM deposition, while
environmental cues (i.e. blood flow, hypoxia, circulating factors) determine the
dynamic interaction between established EC and the surrounding membrane 18.
However, the precise mechanisms regulating ECM assembly by EC and its
supporting roles are still unknown 18,32.
Each of the ECM proteins plays a different role in the endothelium. For
instance, collagens are a class of matrix protein, with at least 27 subtypes 33.
Collagen IV is the predominant subtype associated with the basement membrane
layer beneath EC 33. Collagens mediate stabilization of an established basement
membrane, particularly under mechanical stress, by forming fibrillar structures
that connect elastin and other matrix proteins to the basement membrane 18,33,34. In
fact, the deletion of collagen IV proves to be embryonically lethal due to defects
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in cell-matrix contacts in regions of high mechanical stress (i.e. in the heart and
blood vessels). As such, collagen IV seems to be a crucial player in basal lamina
assembly and vessel development 34. On the flip side, excess collagen is the
vasculature can lead to vessel fibrosis and increased stiffness 34. Gelatin, a product
of degraded insoluble collagen, is a commonly used biomaterial in the research
field, with uses ranging from tissue engineering to producing a cell-interactive
coating for culturing cells 35. This is possible due to the similarity of gelatin to
collagen, in terms of adhesion molecules and receptors, while reducing the cost of
production and immunogenic effects, as compared to pure collagen 35.
An important proteoglycan found throughout the ECM is fibronectin. This
440kDa protein is often implicated in regulating cell-matrix interactions and cell
function, due to its interaction with vascular cells, including EC, and regulation of
cellular adhesion, growth, and differentiation 33,34. Additionally, fibronectin
deposition promotes synthesis, organization, and stability of other matrix proteins
(i.e. collagen I and III, and thrombospondin), and vascular remodeling through
leukocyte infiltration and expression of adhesion molecules 34.
Laminin, a class of glycoproteins, is thought to be the main biologically
active component of the vascular ECM and plays a critical role in maintaining the
integrity of the endothelium 18. The two main isoforms of laminin in the
endothelium are laminin 8 and laminin 10, each expressed in varying degrees
depending on the state of the vessels (new vs. established) and the environmental
cues 36. Laminins are crucial for dictating cell migration and vessel stability
during angiogenesis and neovascularization 36. In fact, during development,
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laminins are the primary determinants of EC plasma membrane assembly and
critical for vessel maturation and branching 32,36. Additionally, laminin can
regulate transmigration of circulating leukocytes and biomolecules across the
endothelium, alluding to a critical role in barrier stability 36
Vitronectin is another glycoprotein found in both the ECM and circulation
34

. While there is limited data on the role of vitronectin in cell-matrix interactions,

it has been shown to regulate vessel remodeling by regulating vascular cell
migration and may also contribute to thrombosis 34. Interestingly, activation of
vitronectin has been shown to decrease EC adhesion and results in poor EC
spreading on vitronectin-coated matrices 37. Furthermore, activated vitronectin
may increase vascular permeability by promoting internalization of inter-cellular
adhesion proteins (i.e. VE-cadherin) 38. These studies imply a significant role of
vitronectin in regulating barrier stability and repair under pathological conditions.
Components of the ECM are highly dynamic and often work in
conjunction with one another. Previous studies analyzing the structure and
function of ECM proteins under basal and pathological conditions suggest
collagen type IV provides structural support to the basal membrane, laminins
convey biological signals to surrounding cells, and proteoglycans act principally
to cross-link the collagen type IV and laminin networks, bind soluble factors such
as growth factors, and are important for the filtration properties of the ECM 36.
Furthermore, the interaction of vascular cells with the basement membrane
maintains endothelial homeostasis by reducing inflammatory gene expression,
inhibiting matrix calcification, and enhancing contractile genes 34. Additionally,
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basement membrane stiffness seems to play a crucial role in determining the
endothelial phenotype- studies have revealed that the differential EC phenotypes
in arterial vs. venous capillaries may be due to the differential stiffness of the
underlying ECM, regardless of differences in flow 39.
Environmental factors, in turn, influence the expression of matrix proteins
and how they interact with cells. Previous studies have shown an upregulation of
laminin under proinflammatory conditions, as well as alterations in other matrix
proteins, alluding to the dynamic nature of the ECM in relation to environmental
conditions 36.

1.3.2 Integrins
Cell-matrix interactions are mediated by the binding of matrix proteins to
cell surface receptors- the most common endothelial receptors that interact with
the matrix are integrins 40. Integrins are a class of heterodimeric proteins
comprised of an α subunit and a β subunit 40. These proteins recognize a sequence
of amino acids (arginine, glycine, aspartic acid (RGD)) found on multiple matrix
proteins, including fibronectin, collagen, laminin, and vitronectin, as well as
certain plasma proteins 40.
Integrins mediate differential functions depending on receptor subtype and
cell type 40. For instance, the α2β1 integrin interacts with laminin in EC but binds
to collagen in most other cell types 40. There are seven integrin subclasses found
in human EC that can bind with varying affinity to ECM components, with α2β1,
α3β1, and αvβ3 having the broadest affinity 40.
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Integrins play an important role in vasculogenesis, angiogenesis, and
maintaining vascular integrity 41. They mediate EC-ECM adhesion and mediate
cell migration through the basement membrane while providing intracellular
signaling cues via tyrosine kinases 41. Modulation of integrin synthesis is highly
dependent on environmental factors- for instance, a paper reported that
combination of tumor necrosis factor α (TNFα) and interferon γ (IFNγ) induced a
70% decrease in the number of αvβ3 integrin molecules 40. In EC, integrins are
typically activated by growth factors (i.e. vascular endothelial growth factor
(VEGF)) and mechanical stress, resulting in the intracellular activation of focal
adhesion kinase (FAK)- this downstream signaling is crucial for dictating
cytoskeletal organization and signal transduction 41.
There is still a limited understanding of the regulation of integrins in EC
and the impact of biochemical signaling induced by integrin-ECM contacts on EC
barrier function. However, clustering of certain integrins (α2β1 and αvβ1
specifically) has been observed around confluent EC borders, with αvβ1 being
associated with focal contacts 40. Furthermore, antibodies targeted to integrin
receptors have been shown to increase EC permeability, leading to barrier
dysfunction 42,43. These results suggest a crucial role of integrins in regulating ECECM interactions and endothelial barrier function, though further work is needed
to elucidate the underlying mechanisms.
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1.3.3 Focal adhesions
Interactions of certain integrins with specific basement proteins promote
the formation of specialized structures called focal adhesions 44. Focal adhesions
are important in regulating the intracellular cytoskeletal structure via stress fiber
formation, which in turn mediates important cell processes, such as mitosis, ECM
deposition, and interactions with cell-binding molecules (i.e. growth factors) 44.
Focal adhesions typically form at regions with specialized interactions
between matrix components, integrins, and the cytoskeleton- typically, these
regions are characterized by strong binding interactions between the cell and the
basement membrane, leading to the belief that focal adhesion may act as the
primary structure for stable cell-ECM attachment, particularly in quiescent cells
44

.
Focal adhesion assembly requires the interaction of multiple binding

proteins, which are all allosterically linked to form large multiprotein complexes
45

. There are more than sixty focal adhesion proteins discovered in vertebrates so

far, and due to the complexity of players involved, the exact mechanism of focal
adhesion regulation is still unclear 14.
Studies have elucidated that the formation of focal adhesions is initiated
through integrin-matrix interactions 14. These initial interactions lead to the
establishment of early cell-ECM adhesion structures called focal complexes
(transient), which can later mature into the more stable FAC 14. Integrin-ECM
interactions lead to the recruitment and activation of numerous downstream focal
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adhesion proteins (i.e. vinculin, talin), which in turn stabilize the newly formed
focal complexes 14,45. Cell-ECM adhesion structures are regulated through Rac
and other members of the Rho GTPase family, possibly through increased actin
polymerization and stabilization of nascent focal complexes 14. Another important
regulatory process in focal adhesion formation is protein phosphorylation of focal
adhesion proteins, namely paxillin and focal adhesion kinases (FAK) 14.
Integrin-matrix interactions regulate FAK recruitment to focal adhesion
sites, where it undergoes autophosphorylation into the active form (i.e.
phosphorylated FAK (pFAK)). pFAK exhibits regulatory functions via
interactions with the plasma membrane and is a crucial linker to the F-actin
scaffold, suggesting an important role in intracellular signaling 45. The
involvement of these multi-domain proteins present in FAC allows for the
formation of an extensive “web” within the cell, that has broad impacts on cellular
processes, including cell-cell interactions 14.
Focal adhesion disassembly can be mediated through intracellular
signaling and degradation of focal adhesion components (i.e. talin degradation),
and proteolytic degradation of the ECM 45. The loss of matrix proteins affects
mechanical tension, while the soluble matrix fragments can signal the activation
of different cellular processes (i.e. angiogenesis) 45. Interestingly, proteases are
often present in proximity to focal adhesion regions, indicating that the levels of
proteases, and the balance between protease activators and inhibitors, may be
important in modulating EC-ECM adhesion by regulating the formation and
stability of FAC 44.
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While the exact function of FAC remains unclear, one potential role of
these complexes may be to mediate stable adhesion of cells to the basement
membrane in vivo (or adhesion to a planar substrate, collagen, or collagenderivatives in vitro) 44. This is suggested by the finding that cells that depend on
cell-matrix adherence to promote function (i.e. fibroblasts, EC) form the more
stable and prominent FAC, whereas migratory cells typically contain fewer and
more transient focal complexes 44. FAC may also play a role in stress fiber
formation and wound repair- during the proliferative stage of wound repair, the
force exerted by the cytoskeleton via focal adhesions can aid in wound
contraction and remodeling of the basement membrane 44.

1.3.4 Function of cell-matrix interactions in endothelial barrier
homeostasis
Under homeostatic conditions and during tissue regeneration, remodeling
of the ECM enables EC to interact with each other, circulating leukocytes, and the
surrounding tissue- these interactions have important implications for cellular
processes, such as development, tumorigenesis, and tissue repair 30. Adhesion of
the EC to the underlying matrix progresses in stages: attachment, spreading, and
finally the organization of the cytoskeleton 44. While growing cells on
physiologically-relevant matrix components (i.e. fibronectin-coated wells) has
been shown to aid initial adhesion, EC can also synthesize and secrete their own
endogenous matrix proteins, which is eventually followed by physiologically
comparable cell spreading and cytoskeletal organization 44. Furthermore, the
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presence of large FAC, primarily situated at cell borders, in quiescent cells (i.e.
EC) compared to smaller, less distinguished, transient focal adhesions in motile
cells suggest an important role of focal adhesions as a mechanism to confer
stability and strength in cellular adhesion 44.
Multiple mechanisms have been implicated in the contribution of cellECM interactions in conferring cell barrier stability. Changes in matrix
composition have been shown to alter the adhesive capacity of cells under
different physiological states (i.e. age, wound healing) 44. For instance,
differential synthesis of certain matrix proteins (i.e. chondroitin) has been
observed in highly migratory cells, which may interfere with binding of cells to
adhesion-promoting matrix proteins (i.e. fibronectin). Changes in membraneassociated components, specifically integrins, may also affect the capacity of cells
to form focal adhesions 44. Studies have shown that these membrane components
are primary targets for regulating changes associated with cellular transformation
decreased adhesion, resulting in reduced capacity for cells to form FAC.
In other cases, while ECM proteins stayed constant, changes in the cells
and their receptor affinity to matrix proteins or cytoskeleton have been implicated
in altered cellular adhesion 44. Activation of proteases at focal adhesion sites may
also be one potential mechanism by which cells disrupt adhesion, leading to
detachment from the basement membrane 44. Specifically, extracellular proteases,
produced during cellular transformation or released during tissue damage or
inflammatory response, may cleave matrix proteins, interfering with cell-ECM
interactions. Furthermore, proteases may also act on FAC proteins directly,
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interfering with the ability to cross-link subunits within the FAC 44. For instance,
talin can be targeted by calcium-dependent proteases, and cleavage of this protein
interferes with downstream interactions with other focal adhesion proteins (i.e.
vinculin) 44.
Extracellular signals, such as proinflammatory cytokines, may also affect
cell-ECM interactions to promote the infiltration of leukocytes into the underlying
tissue 46. Previous studies have shown that under basal conditions, T cell
extravasation is inhibited by endothelial focal adhesions by acting as a physical
barrier for trans-endothelial migration of leukocytes. However, treatment with
TNFα, a proinflammatory cytokine, revealed larger subendothelial spaces and
fewer focal adhesions near EC junctions 46. This indicates an important role of
cell-ECM and cell-cell interactions, mediated through focal adhesions, in
remodeling the basal layer to promote leukocyte migration 46.
The process through which cell-matrix interactions can mediate PMVEC
barrier function is summarized in Figure 1-1.
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Figure 1-1. Regulation of PMVEC barrier function through PMVEC-ECM and
inter-PMVEC interactions. Under basal conditions in the endothelial monolayer,
integrin receptors interact with ECM proteins to form cell-matrix adhesions. This
interaction promotes the assembly of focal adhesion complexes (FAC) through
phosphorylation of focal adhesion kinase (pFAK) which recruits further downstream
proteins. FAC strengthens integrin-ECM interactions, and interacts with intracellular
components, like F-actin filaments, to stabilize adherens junctions. The cumulative effect
of these pathways mediates PMVEC-ECM and inter-PMVEC interactions, supporting
PMVEC barrier function.
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1.4 Metalloproteinases
Metalloproteinases are a family of Ca2+- and Zn+-dependent
endopeptidases found in the tissue microenvironment 47. These include matrix
metalloproteinases (MMPs), the membrane-bound a disintegrin and
metalloproteinases (ADAMs), and their close derivatives, ADAM with
thrombospondin motifs (ADAMTSs) 47. While first discovered through their
function in remodeling the extracellular matrix, later studies have suggested
immunomodulatory roles of metalloproteinases in the body, including those
related to EC barrier function (i.e leukocyte extravasation) 47.

1.4.1 Metalloproteinase structure and activity
Metalloproteinases are highly preserved in animals, with studies
identifying at least 23 unique MMPs and 22 ADAMs in humans- of these, at least
12 demonstrate proteolytic activity 47. Most metalloproteinases, whether soluble
or membrane-bound, share a common structural phenotype, including a signaling
peptide, a pro-peptide domain, and a catalytic domain 48. The pro-peptide is
responsible for maintaining the enzymes in an inactive conformation by binding
to the Zn+ or Ca2+ present in the active site until an external stimulus disrupts the
interaction 48.
Different subtypes of the metalloproteinase family may have a slight
variation in structure, including MMPs and ADAMs/ ADAMTSs. For instance,
membrane-type MMPs (MTMMPs), in addition to the base structures mentioned
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above, contain a transmembrane domain to anchor the protein to the cell surface
membrane 47. ADAMs have a similar organization as MTMMPs due to being
primarily membrane-bound, while also containing a disintegrin domain and some
unique regions to allow for substrate interaction with adjacent cells 47.
Both soluble and membrane-anchored metalloproteinases process their
substrates by the clipping or shedding of specific surface proteins, and by
regulating intramembrane proteolysis 47. Metalloproteinases are capable of
interacting with circulating cytokines, chemokines, and growth factors, and can
alter their bioactive state and local delivery 47. Additionally, metalloproteinases
can mediate shedding of cell surface receptors, which in turn alters the surface
composition of cells and their ability to interact with extracellular signals 47.
Furthermore, receptor cleavage results in intra-membrane proteolysis, causing
downstream intracellular signaling and post-translational modifications 47.
Due to the ubiquitous role of metalloproteinases in cells and tissue, their
expression is highly regulated. Metalloproteinases are often secreted as inactive
zymogens and are catalytically activated only after the cleavage of the inhibitory
pro-peptide domain 47. Additionally, compartmentalization of certain MMPs in
specific intracellular and extracellular regions may be crucial for controlling
MMP specificity and activity through substrate-specific degradation of the
basement membrane 47,48. Multiple factors, including cytokines, growth factors,
and hormones, can also interact with metalloproteinases and mediate their
expression, as can cell-ECM interactions via integrins 48. Furthermore, activated
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metalloproteinases can be inhibited by a family of unique inhibitory proteins
termed the tissue inhibitors of metalloproteinases (TIMPs) 47.

1.4.2 Function of metalloproteinases in endothelial barrier
homeostasis
Metalloproteinases are involved in numerous biological processes,
including matrix remodeling, cell proliferation, migration, and apoptosis 49. For
instance, MMP13 plays an important role in bone development and repair, as
demonstrated by elevated levels of MMP13 in chondrocytes and osteoblasts,
which promotes normal bone remodeling via ECM degradation 50. MMPs have
also been shown to play an important role in angiogenesis (both physiological and
pathological) through their contribution to EC tube formation 51. Additionally,
MMPs can regulate immune functions- previous studies have shown that these
proteases facilitate leukocyte transmigration through the vascular wall and may
also be involved in negative feedback mechanisms to regulate the inflammatory
response 52. As such, metalloproteinases demonstrate functions that extend
beyond ECM degradation- through their ability to cleave cytokines, chemokines,
and cell surface proteins, these enzymes are critical mediators in regulating
immune function, tissue repair, cell differentiation, and transformation 53.
In mature, healthy adult tissue, metalloproteinase levels are generally lowhowever, when subjected to pathologic stimuli (i.e. injury, disease), increased
expression of certain metalloproteinases has been observed 49. For instance,
patients with ALI demonstrate elevated MMP9 expression, which may be a
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contributor to oedema via degradation of tight junction proteins between adjacent
brain EC (i.e. occludins and claudin-5) 54. Other studies have implicated MMPs
and ADAMS (i.e. MMP7, ADAM10, ADAM12) in cleaving VE-cadherin, an
important component of adherens junctions 11,25. These findings suggest that
metalloproteinases can regulate MVEC interactions and affect vascular
permeability 11,23,55.
While some metalloproteinases target intercellular junctions, others act
notably on the ECM, playing a role in its maturation, turnover, and assembly 53. In
fact, the first metalloproteinase, MMP1 (initially termed collagenase for its action
on collagen) was discovered through its degradative properties of the ECM during
tadpole tail metamorphosis 56. ADAMTSs, similar to ADAMs except for the fact
that they are secreted, have also recently been shown to be key participants in
ECM turnover and matrix assembly during morphogenesis, via activation of
matrix precursor proteins 53. However, while metalloproteinases have important
roles in physiologic ECM remodeling, excessive protease expression can be
detrimental to tissue functioning.
Metalloproteinase expression can become aberrant under certain disease
conditions, particularly in response to an inflammatory stimulus, leading to
excessive proteolysis and disease progression if not controlled 47. MMPs and
ADAMs are involved in vascular remodeling under pathological conditions and
can affect endothelial barrier function through a disruption of cell-matrix
interactions 11,23,25. For instance, both MMP2 and -9 have been associated with
increased PMVEC permeability via degradation of matrix proteins (i.e.
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fibronectin, laminin, and collagen IV) 11. Metalloproteinase overexpression can be
mediated through multiple factors, including proinflammatory cytokines (i.e.
TNFα), certain pathogens (i.e. Streptococcus pneumoniae), or a dysregulation of
the metalloproteinase and TIMP balance 11,57. As such, metalloproteinases can
influence endothelial function through multiple mechanisms, and aberrations in
their homeostatic activity may significantly alter barrier integrity, particularly
under proinflammatory conditions.

1.5 Tissue inhibitors of metalloproteinases (TIMPs)
Excessive ECM degradation and shedding of surface molecules are
associated with numerous pathologies, including inflammation, degenerative
diseases, and cancer 58. As such, the balance between metalloproteinases and their
regulators is crucial for maintaining the equilibrium between matrix deposition
and remodeling 58. Among the most prominent endogenous metalloproteinase
inhibitors are the TIMPs 59.

1.5.1 TIMP structure, localization, and activity
TIMPs are a family of proteins, with four mammalian subtypes- TIMP1 to
-4 58. Each of the TIMPs varies in its binding affinity to the various
metalloproteinases, with TIMP3 having the broadest inhibitory profile by
efficiently targeting most MMPs, and several ADAMs and ADAMTSs 59. Human
TIMPs are comprised of 2 domains, an N-terminal domain and a C-terminal
domain 60. Generally, the N-domain interacts with metalloproteinases at their
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active site and causes inhibition, while the C-domain is responsible for proteinprotein interaction 11. However, some studies have revealed that the C-terminus
may be involved in activating certain proMMPs (i.e. proMMP2 and -9) and may
regulate cellular activities independent of metalloproteinase action 11,61.
Much like metalloproteinases, TIMPs demonstrate tissue-specific activity,
and can be constitutively active or expressed following transcriptional signaling
under different stimuli (i.e. cytokines, growth factors) 59. TIMP1 and -2 are
expressed in most mammalian tissue. However, TIMP1 expression may be
restricted to certain regions within the organ- for instance, in the central nervous
system, TIMP1 activity is restricted to regions of high neuronal plasticity, such as
the cerebellum and the hippocampus 59. TIMP3 is also expressed in many tissues
and is particularly important as a matrix protein in the basement membrane of
certain organs (i.e. the eyes and the kidneys) 59. Unlike the other TIMPs, TIMP4
has a very limited and specific distribution (the heart, kidneys, pancreas, colon,
testes, brain, and adipose tissue) and its functionality remains to be fully
elucidated 59.
TIMPs are highly multifunctional proteins with various biological
functions, such as modulation of cell proliferation, cell migration and invasion,
anti-angiogenesis, anti- and pro-apoptosis, and neuronal plasticity 60. Due to their
influence on metalloproteinase activity, TIMPs can mediate cellular function
through signaling pathways related to ECM catabolism, cell adhesion molecules,
cytokines, and growth factors 59. However, the exact role of TIMPs in regulating
ECM remodeling is still debated, largely due to contradictory evidence from
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studies showing opposing effects of respective TIMPs 11. For instance, a previous
study revealed that knocking out the Timp3 gene increased collagen accumulation
and fibrosis post-bleomycin-induced lung injury 11. While it was suggested to be
due to persistent inflammation, these findings contradict the initially accepted
belief that decreased TIMP expression leads to ECM degradation, while excess
ECM deposition would be due to increased TIMP levels 11.
Interestingly, recent studies have indicated some metalloproteinaseindependent functions of TIMPs through their interaction with specific cell
surface receptors 59. While the exact mechanisms are still unknown, these findings
highlight the complex mechanisms involved in the TIMP-metalloproteinase
balance and the need for further studies to elucidate the role of this balance
depending on the specific underlying process.

1.5.2 MMP-dependent function of TIMPs
The function of TIMPs is highly varied, depending on the specific TIMP,
the microenvironment, and the metalloproteinase in question 11,58,62. For instance,
TIMP1 is more restricted in its inhibitory range on metalloproteinases than the
other TIMPs, with activity limited to membrane-type MMPs, MMP6, -14, and -24
60

. However, its affinity for specific MMPs (i.e. MMP-3, MMP-7) is superior to

TIMP3 and TIMP4 60.
Most of the previous work investigating TIMP function is a product of
gene knockout studies in mice 60. While ablating Timp1 or -2 respectively is not
associated with any severe physiological aberrations, Timp1 and -2-deficient mice
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do manifest abnormalities related to matrix remodeling (i.e. impaired neurological
and motor-function) following a pathological challenge 59. Interestingly, Timp3null mice have significantly higher abnormalities, even under basal conditions,
than other Timp knockout mice, with the ablated mice showing emphysema-like
alveolar damage and apoptosis of mammary epithelial cells 59. These results have
been associated with increased metalloproteinase activity (i.e. MMP9), strongly
suggesting that TIMP3 may be a critical regulator of MMP activity 59.
All TIMPs have been shown to inhibit MMPs to some degree 48. TIMP1
may regulate cell signaling by targeting specific MMPs (i.e. MMP7, MMP9) 11. A
gene knockout study revealed that Timp1-null mice had increased MM7
expression in the airway epithelium upon naphthalene exposure, suggesting a
strong relationship between TIMP1 and MMP7 48. Furthermore, TIMP1 can
inhibit MMP7-dependent syndecan-1 shedding which may restrict epithelial cell
migration 11. TIMP1 may also inhibit MVEC migration by limiting the action of
MMP9 on cell surface proteins, reducing VE-cadherin and platelet endothelial
cell adhesion molecule 1 (PECAM1) shedding 11.
Some TIMPs may have contradictory actions on metalloproteinases,
including activation of proMMPs 11,63,64. For instance, latent MMP2 can bind to
TIMP2 for complete activation of the protease 11,63. The N-domain of TIMP2
binds to MMP14, while its C-domain binds to the inactive MMP2, which
mediates the interaction between MMP14 and MMP2, leading to the activation of
MMP2 11.
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Certain TIMPs can also interact with the ADAM and ADAMTS subtypes
of the metalloproteinase family, particularly TIMP3 11,65. An important substrate
of TIMP3 is ADAM17, also known as the TNFα converting enzyme (TACE) 11.
TACE is an important enzyme in mediating inflammation through its actions on
membrane proteins 11. For instance, ADAM17 catalyzes the shedding of
membrane-bound TNFα and other pro-inflammatory cytokines, and transforming
growth factor α (TGFα) 11,66,67. TGFα is a ligand of the epidermal growth factor
receptor (EGF), which, when activated, leads to cell proliferation, expression of
IL8, and leukocyte migration 11. Timp3 knockout studies have shown that a lack
of TIMP3 is associated with increased inflammation following an insult (i.e.
bleomycin-induced lung injury)- this may be due to higher ADAM17 expression,
resulting in increased TNFα shedding 48. As such, TIMP3 may play an important
role in mediating the immune response by regulating the processing of TNFα via
TACE 59. These studies have also revealed an association between lack of TIMP3
and increased substrate degradation (i.e. aggrecan cleavage), alluding to the role
of TIMP3 in inhibiting ADAMTS-dependent degradation of matrix components
and ECM turnover 11,48.

1.5.3 MMP-independent function of TIMPs
While most studies focus on the role of TIMPs in relation to
metalloproteinase inhibition, recent data support multifunctional properties of
TIMPs in regulating processes unrelated to or only partially related to
metalloproteinase activity 68. These studies indicate that TIMP-receptor binding is
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involved in numerous important cellular processes, such as regulating cell
proliferation, apoptosis, and angiogenesis 68.
TIMP1 and -2 have been implicated in regulating mitogenic activities in
various cells, including mesenchymal and epithelial cells, through independent
receptor signaling 11,69,70. It has been thought that TIMP1 promotes cell growth by
targeting the tyrosine kinase/ mitogen activated protein kinase (MAPK) pathway,
while TIMP2 targets protein kinase A to activate the Ras/ phosphoinositide 3kinase (PI3K) complex 68. Conversely, TIMP1 and -2 can suppress cell
proliferation and apoptotic signaling in certain cells by targeting specific
antibodies (i.e. CD63) and integrin complexes (i.e. α3β1) 68. In fact,
overexpression of TIMP1 and -2 has been linked to various cancers, including
ductal breast cancer development, apoptotic-resistant Burkitt’s lymphoma, and
murine melanoma 68. Interestingly, TIMP2 has shown some pro-apoptotic activity
in specific cells (i.e. apoptosis of activated T cells), indicating the need for further
research on establishing the exact role of TIMP2 in apoptosis 68.
TIMP3 has also shown some apoptotic function in specific cell types- for
instance, overexpression of TIMP3 in pulmonary artery EC is associated with
increased apoptosis, likely be due to inhibition of a FAK-dependent survival
pathway 7111. Additionally, recent studies have demonstrated TIMP3’s function as
a potent inhibitor of angiogenesis 68. TIMP3 can bind to the VEGF receptor on
EC, subsequently blocking the interaction of its endogenous ligand, VEGF, and
inhibiting the downstream pathway 68. Meanwhile, TIMP3 can also target the
angiotensin II type 2 receptor, and the combined effect of TIMP3 on inhibiting the
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VEGF pathway and upregulating angiotensin II type 2 receptor activity results in
cumulative inhibition of angiogenesis 68.
TIMP3 may also regulate cell proliferation, though whether it promotes or
inhibits the process depends on the cell type 72. Some studies have demonstrated
an association between TIMP3 and enhanced proliferation in chicken fibroblasts
and bronchiole epithelial cells during embryonic development, while others have
indicated that TIMP3 inhibits vascular smooth muscle cell and EC proliferation 72.
Interestingly, the inhibition of cellular proliferation may be mediated through
metalloproteinase-independent processes, as studies have demonstrated that
overexpression of TIMP3 inhibited cell proliferation without significantly altering
inhibition of protease activity- this may be due to the role of TIMP3 on p21 and
p27, both of which inhibit cyclin-dependent kinases, at least as demonstrated in
cardiomyocyte proliferation 72.
The metalloproteinase-dependent and metalloproteinase-independent roles
of TIMP3 are further summarized in Figure 1-2.
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Figure 1-2. Proposed metalloproteinase-dependent and metalloproteinaseindependent functions of tissue inhibitor of metalloproteinases 3 (TIMP3) in
microvascular endothelial cells 11. A) In the presence of TIMP3, MMPs and ADAM 17/
TACE are inhibited. The structure and composition of the ECM and MVEC intercellular
junctions are maintained, while leukocyte adhesion and extravasation are limited. B) In
the absence of TIMP3, increased MMP activity leads to degradation of the ECM and
proteins associated with intercellular junctions. Increased ADAM17 activity promotes the
release of TNFα, enhancing the proinflammatory response. Expression of leukocyte
receptors, such as ICAM1 and VCAM1, is increased on the surface of MVEC.
Additionally, the shedding of these receptors by metalloproteinases may promote
leukocyte extravasation into the underlying tissue. Membrane-bound TGFα is also shed
from the cell surface by ADAM17, resulting in binding to and activation of epidermal
growth factor (EGF) receptors to promote cell proliferation, cell migration, and
angiogenesis. C) TIMP3 binds the VEGF receptor, inhibiting its downstream signaling
cascade by preventing interaction with and binding of its ligand, VEGF-A. TIMP3 also
binds to and activates the Angiotensin 2 (AT2) receptor II. The combined effects of
VEGF receptor inhibition and AT2 receptor II activation decreases cell proliferation and
migration, inhibits angiogenesis, reduces vascular permeability, and inhibits leukocyteEC interaction. D) The absence of TIMP3 allows VEGF to bind to its receptor, activating
the MAPK, PKB, PKC, and NOS pathways and leading to increased expression of the
Egr3, and phosphorylation of proteins associated with MVEC intercellular junctions.
Moreover, the AT2 receptor II remains inactivated due to the lack of TIMP3 binding.
Overall, the combined effects of VEGF activation and AT2 receptor II inactivation result
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in increased cell proliferation and migration, increased angiogenesis, increased
expression of cell surface adhesion molecules, leading to enhanced leukocyte-EC
interaction, and increased vascular permeability.
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1.5.4 The role of TIMPs in EC barrier function
Due to the impact of TIMPs in various cellular functions, these inhibitors
may be crucial regulators of MVEC interaction and barrier function 11,73. There is
some evidence suggesting that the metalloproteinase-dependent role of TIMPs is
responsible, as increased metalloproteinase activity has been associated with
enhanced cerebral microvascular permeability, and the inhibition of
metalloproteinase activity partially rescues the leak 74. Other studies have shown
that the addition of synthetic metalloproteinase inhibitors or recombinant TIMP1
appears to reduce VE-cadherin cleavage 74.
Inflammation could be a driving force of TIMP dysfunction and the
subsequent increase in metalloproteinase activity. While TIMPs contribute to
cytokine and cytokine receptor turnover, proinflammatory cytokines themselves
(TNFα, interleukin 1β (IL1β), and IFNγ) can differentially regulate MMP and
TIMP expression 55. For instance, previous studies have shown that
proinflammatory cytokines up-regulate TIMP1 expression in both rat brain
microvascular EC and astrocytes, while TIMP2 remained unchanged 55.
TIMP3, in particular, is of great research interest due to its significant
presence within vascular tissue- emerging data suggests that TIMP3 can regulate
microvascular barrier function, as mice lacking TIMP3 have increased leak of
Evans blue (EB) dye-labeled albumin within the snout and kidneys, due to the
absence of TIMP3 in pericytes 74. Other studies have shown that mesenchymal
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stem cell-derived TIMP3 decreases cerebral microvascular leak in a model of
traumatic brain injury 74.
Additionally, TIMP3 is shown to be crucial in maintaining lung
homeostasis. Timp3-/- lungs in murine embryos demonstrated reduced matrix
protein abundance due to increased activity of TIMP3-inhibited
metalloproteinases and decreased FAK signaling 75. Furthermore, treatment with a
broad-spectrum metalloproteinase inhibitor increased FAK signaling and matrix
protein abundance, restoring appropriate bronchiole branching in the developing
lungs 75. Under inflammatory conditions, Timp3-/- mice demonstrated enhanced
neutrophil influx in the lungs and a longer duration of inflammation, as compared
to WT mice 76. These findings indicate an important role of TIMP3 for
maintaining normal cell-ECM interactions in the lungs- understanding the
contributing mechanisms under basal and proinflammatory conditions may be
crucial for targeting disruption of the EC barrier function under pulmonary
dysfunction.

1.6 Rationale
While numerous studies have focused on specific aspects of the
endothelium and its function in the body, the precise role of cell-matrix
interactions in regulating pulmonary microvascular endothelial barrier function
remains a mystery. Some studies have suggested that decreased EC-ECM
interactions, as indicated by altered pFAK abundance and distribution, is
associated with an impaired endothelial function, resulting in oedema and lung
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dysfunction 15,77,78. However, many studies have shown conflicting and often
opposing results in pFAK change, with the results being highly dependent on the
stimulus, cell-type, and duration of study 15,78–82. There is a persistent need to
study the role of cell-ECM interactions, via pFAK analysis, in PMVEC barrier
function, particularly under cytokine treatment, as proinflammatory conditions
like sepsis are closely associated with accumulation of pulmonary oedematous
fluid and lung dysfunction.
Interestingly, very few, if any, studies, have looked at the role of TIMPs in
relation to cell-matrix interactions and EC barrier stability. Previous work in our
lab has shown that TIMP3 plays an important regulatory role in PMVEC barrier
function, as lack of TIMP3 via murine knockout studies revealed a compromised
PMVEC barrier, causing increased protein leak in the pulmonary vasculature- this
was particularly prominent under proinflammatory conditions 74. The
metalloproteinase-dependent action of TIMP3 is thought to be the main
contributor to PMVEC barrier stability, as studies using a broad-spectrum
metalloproteinase inhibitor (GM6001) in PMVEC derived from Timp3-/- mice
rescued the augmented leak seen in the knockout mice 11.
Many studies trying to elucidate the mechanism by which TIMP3 and
metalloproteinase activity affect PMVEC interactions explored the disruption of
intercellular junctions. Prior studies have demonstrated that multiple
metalloproteinases (i.e. MMP7, ADAM10, and ADAM12) cleave VE-cadherin,
one of the primary junctional proteins responsible for PMVEC barrier stability 11.
However, few studies have focused on the impact of TIMP3 in relation to cell-
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ECM interactions, including via metalloproteinase activity. There is some
research suggesting that degradation of the matrix proteins (i.e. fibronectin,
laminin, type IV collagen) by MMP2 and -9 is associated with increased PMVEC
permeability both in vivo and in vitro 11,83. Additionally, increased FAK
phosphorylation has been associated with MMP expression in some cancer cell
lines, particularly under cytokine treatment 84. Furthermore, some studies
indicated that while certain metalloproteinases (i.e. MMP2, -9) decreased cell
survival post-injury, and that inhibition of these metalloproteinases enhanced cell
survival, ECM-integrin-dependent FAK activation rescued cell survival, even
when MMPs remained activated 85. While these studies suggest an important
association between metalloproteinase activity and integrin-mediated pFAK
activation, there is a limited understanding of the overall role of TIMP3 in
regulating cell-ECM interactions in PMVEC barrier function, and how this may
be altered under proinflammatory conditions.

1.7 Objectives
Considering the lack of data on the role of TIMPs in metalloproteinasemediated EC-ECM interactions in the pulmonary vasculature, I proposed to:
1. Examine the role of TIMP3 in regulating PMVEC permeability.
2. Examine the role of TIMP3 in regulating PMVEC-ECM interaction.
To achieve my objectives, I employed the novel XperT-permeability assay to
visualize individual PMVEC-specific localized protein (i.e. avidin) leak in
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relation to VE-cadherin dissociation, and compare the specific regions and extent
of PMVEC permeability in WT vs. Timp3-/- PMVEC under basal and
proinflammatory conditions.
To better understand potential differences in PMVEC-ECM interactions
and permeability between WT and Timp3-/- PMVEC, I also examined basal
adhesion of WT and Timp3-/- PMVEC to commonly used cell-culture adhesion
coatings (i.e. gelatin) and matrix proteins (collagen, fibronectin, vitronectin,
laminin). Additionally, I employed the use of confocal microscopy to assess
potential differences in pFAK aggregations between WT and Timp3-/- PMVEC
under basal vs. proinflammatory stimuli.
Lastly, I repeated the individual PMVEC leak studies in WT and Timp3-/PMVEC using broad-spectrum metalloproteinase and FAK inhibitors
respectively, to better assess the role of metalloproteinases and pFAK in PMVEC
barrier permeability, and the impact of TIMP3 in mediating metalloproteinasedependent PMVEC-ECM adhesion.

1.8 Hypothesis
Based on the prior data regarding TIMP3 and metalloproteinase function,
and the importance of PMVEC-ECM interactions in normal cell function, I
hypothesized that TIMP3 maintains PMVEC barrier function by promoting
PMVEC-ECM interactions.
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Chapter 2

2

Methodology

2.1 Isolation of murine pulmonary microvascular endothelial
cells (PMVEC) for in vitro analysis
In order to study the role of TIMP3 in regulating the pulmonary
microvascular barrier function, under both basal conditions and a
proinflammatory environment, PMVEC were isolated from healthy male WT and
Timp3-/- mice and cultured as performed routinely within out lab 86,87.
Briefly, isolated lung tissue was minced and digested using 0.3%
collagenase in Hank’s Balanced Salt Solution (HBSS, #14170-112, Invitrogen).
The cells were filtered through a 100μm pore mesh sieve, followed by a period of
incubation with magnetic microbeads (Dynabeads M 450 sheep anti-rat IgG,
#11035, Dynal Biotech Inc., Lake Success, NY) that were coupled to anti-platelet
endothelial cell adhesion molecule (PECAM) antibodies (Rat anti-mouse CD31
monoclonal antibody, #557355, BD Pharmingen, Franklin Lakes, NJ). Following
the magnetic capturing of PMVEC (MPC magnet, Dynal Biotech Inc., Lake
Success, NY), cells were washed, suspended in a growth medium (Dulbecco’s
modified Eagle’s medium [DMEM] supplemented with 20% heat-inactivated fetal
bovine serum [FBS], #11885-092, Invitrogen, Carlsbad, CA; 1%
Penicillin/Streptomycin [10 000 U/mL], #15140122, Invitrogen; 2% [4-2[2-
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hydroxyetyl]-1-piperazineethanesulfonic acid] [HEPES] buffer [1M], #15630080, Invitrogen) and seeded into a 1% gelatin-coated cell culture flask. The cells
were incubated at 37°C with 5% carbon dioxide (CO2), with weekly assessments
to ensure appropriate morphology. Once achieving approximately 90%
confluency, the cultured PMVEC were stained with fluorescent acetylated-low
density lipoprotein (LDL) (Biomedical Technologies, # BT902, Stoughton, MA)
and assessed by immunofluorescence, as well as stained with fluorescentlylabeled antibodies against endothelial cell markers (i.e. CD31, CD34, CD146, and
CD202) and assessed by flow cytometry to ensure the purity of cell type.
Collectively, these processes resulted in a PMVEC culture that was 99%
homogeneous. PMVEC were then transferred to cell culture plates and grown in
supplemented DMEM growth medium and incubated at 37°C with 5% CO2 until
forming a monolayer of 90% to 95% confluency (approximated). All experiments
were conducted on PMVEC between passages 5 to 10.

2.2 Assessment of PMVEC barrier permeability
2.2.1 Assessing PMVEC localized permeability using the XperTpermeability assay
Localized barrier permeability around murine PMVEC under basal and
proinflammatory conditions was studied by implementing a derivation of the
XperT-permeability assay as previously used in our lab 88,89. In brief, WT and
Timp3-/- PMVEC were grown on a layer of biotinylated gelatin in 48-well tissue
culture plates. The cells were maintained in supplemented DMEM growth
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medium until a 90% to 95% confluent monolayer was formed. PMVEC were then
stimulated with phosphate-buffered saline (PBS) (basal conditions) or cytomix
(an equimolar mixture of TNFα, IL1β, and IFNγ to mimic proinflammatory
conditions, 30 ng/mL) for 5hr at 37°C with 5% CO2. Following stimulation,
fluorescently-labeled avidin (Invitrogen, Avidin, green 488, lot 1888323,
2.5mg/ml) was added into all wells (control and treatment) (Figure 2-1). After 3
min, the avidin was removed from each well and PMVEC were washed 3 times
with PBS.
PMVEC were fixed in ice-cold methanol and stained following an
established immunostaining protocol used in our lab 74. In brief, 0.1% Triton-X
was added to each well to permeabilize cells. After 30min incubation at room
temperature, PMVEC were washed with PBS 3 times and 3% bovine serum
albumin (BSA) in PBS was then added to each well to block off-target sites.
Following blocking, PMVEC were stained with rabbit anti-VE-cadherin antibody
suspended in 1% BSA/PBS (1:100; Invitrogen, ab33168, 0.4ug/mL). After 2hr,
PMVEC were washed with PBS 3 times and then stained with goat anti-rabbit
antibody conjugated to Alexa Fluor 594 in 1% BSA/PBS (1:500; Invitrogen, cat #
A-11012, 2mg/mL). After 1hr, PMVEC were again washed with PBS 3 times and
then stained with Hoechst counterstain (Hoechst 33342, 10mg/mL) for 10min.
PMVEC were then washed with PBS 5 times and placed at 4°C in PBS. Cells
were imaged within two days of fixing using fluorescent microscopy (Zeiss
Axiovert 200M Inverted Microscope; Carl Zeiss Canada, Toronto, Canada) at
20X magnification.
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Figure 2-1. Graphic representation of the XperT-permeability assay.
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2.2.2 Quantification of total avidin leak and localized avidin diffusion
All raw images were analyzed using ImageJ software. A central section of
the image was selected within ImageJ (parameters preset by software) to analyze
the avidin signal in the given region- this was applied to all 5 images acquired per
well (Figure 2-2). To quantify total avidin using ImageJ, the regions of avidin
signal were selected and all background fluorescence was subtracted (Figure 2-2).
The highlighted avidin regions were converted to binary; using an ImageJ plugin
(Morpholib, set at Quasi-Euclidean), the regions were converted to grayscale and
the small avidin leak spots selected individually. (Figure 2-2). This selection
criteria allowed ImageJ to differentiate between avidin regions that were in
proximity and count them as separate signals (Figure 2-2). The selected region
was then highlighted and all ‘particles’ were analyzed (threshold was set at a pixel
range of 100-infinity, and any cut-off regions at the edge of the selected image
were excluded) (Figure 2-2). The regions separated by the MorphoLib plugin had
to be individually selected and added to the total count (Figure 2-2). The total
number of spots was measured, as was the total avidin area.
To assess localized avidin diffusion with respect to the VE-cadherinstained cell border, the final image showing the outline of the total avidin regions
was merged with the image from the VE-cadherin channel (Figure 2-2). This
provided an outline of all avidin spots superimposed over the VE-cadherin image
(Figure 2-2). To quantify avidin diffusion, the distance from the VE-cadherin
border to the edge of the avidin outline was measured perpendicular to the VE-
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cadherin border (Figure 2-3). This ensured representative measurement of the
extent to which the PMVEC-ECM interaction was disrupted to allow for avidin to
leak beneath the cells (Figure 2-3). Additionally, only one measurement was
made per avidin region (Figure 2-3). This protocol was repeated sequentially for
all avidin regions in the selected region of the VE-cadherin image, and the length
of each measurement calculated (Figure 2-3).
The above protocols were followed for all raw images with results per
image being averaged within the treatment groups. Per treatment group, 5 images
were acquired, and the experiments repeated 3 times.
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Figure 2-2. An example of the quantification of total avidin fluorescence and avidin
diffusion length.
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Figure 2-3. An enlarged example of measuring avidin diffusion length.
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2.3 Assessment of PMVEC-ECM adhesion
EC adhesion to matrix proteins was assessed in male murine WT and
Timp3-/- PMVEC under basal conditions, using previously established adhesion
protocols. The cell-matrix interactions were assessed under static conditions,
using two types of assays : a) gelatin-coated adhesion assays, where the PMVEC
were seeded onto a gelatin-coated 96-well plate, and b) ECM cell culture
optimization arrays, where the PMVEC were seeded into a commercially acquired
96-well plate containing four common matrix proteins at varying concentrations.

2.3.1 Assessing PMVEC adhesion to gelatin
Assays testing adhesion of different cell types under various stimuli have
been previously established 90–92. Thus, a generally accepted adhesion assay
format was adopted and optimized to test PMVEC adhesion to gelatin (Molecular
Probes, Vybrant Cell Adhesion Assay Protocol (V-13181).
Under sterile conditions, 0.1% gelatin was added to each well of a blackwalled 96-well tissue culture-treated plate with four wells per plate left empty to
provide gelatin-free control wells. The plate was incubated for 60min at room
temperature, after which time, the wells were washed 3 times with sterile PBS.
The final wash was aspirated before use.
Before seeding, PMVEC were suspended in phenol red-free DMEM
containing 0.1µM calcein-AM and placed on tube rotator for 20min at 37°C and
5% CO2. Following calcein AM incubation, PMVEC were seeded in quadruplets
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into the 96-well plate at 30,000 and 60,000 cells per well. An initial measurement
of the calcein fluorescence was recorded (excitation: 485nm; emission: 520nm)
using a Victor 3 multilabel fluorescence microplate reader. The plate was then
incubated at 37ºC and 5% CO2 for 6hr and 16hr, in addition to pilot experiments
at 1hr, 2hr, 4hr, and 24hr, to provide a comprehensive overview of cell-matrix
adhesion.
Following the respective incubation period, the cells were washed 3 times
with sterile PBS. The initial adhesion experiments altered the force of the wash
(gentle vs. strong), the number of washes (1, 2, or 4 washes), and wash media
(PBS vs. phenol red-free media). Following aspiration of the final wash, 200uL of
phenol red-free DMEM was added to all wells and the final calcein fluorescence
was measured, as per the above parameters.

2.3.2 Assessing PMVEC adhesion to ECM proteins
Commercially available ECM optimization kits (Millipore, Cat. No.
ECM541) were used to assess PMVEC adhesion to collagen I, fibronectin,
laminin, and vitronectin. ECM proteins were plated within the 96-well plates in
triplicate at concentrations ranging from 20 μg/mL to 0.125 μg/mL. The plate also
contained BSA coated wells (negative controls) and non-coated wells (blank
control). Cell adhesion was assessed according to the manufacturers
recommended protocol.
Briefly, all 96 wells of the ECM plate were blocked with 30% BSA in
PBS for 1hr at room temperature. The BSA was aspirated before adding cells. WT
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and Timp3-/- PMVEC in serum-free DMEM were then added to each well at a
final concentration of 50,000 cells per well. The plates were incubated for 2hr at
37°C and 5% CO2. Following incubation, all wells were washed gently 3 times
with serum-free DMEM. The provided cell stain was then added to each well to
stain and fix the PMVEC. After 10min, the cell-stain solution was aspirated, and
the wells were washed 5 times with PBS. Extraction buffer (provided by the
manufacturer) was then added to all wells and the plate was placed on a gentle
rotator for 10min at room temperature. Finally, the absorbance measured using a
Thermo Ascent plate reader at 570nm.

2.4 Assessment of phosphorylated focal adhesion kinase
(pFAK) content in PMVEC
2.4.1 Assessing the impact of gelatin on pFAK abundance in PMVEC
To study pFAK protein in murine PMVEC under basal vs.
proinflammatory stimuli, WT and Timp3-/- PMVEC were seeded on glass
coverslips that were coated with gelatin. These coverslips were placed in 24-well
plates, and the PMVEC were seeded at 50k/ well. The cells were grown in
supplemented DMEM growth medium until reaching 90%- 95% confluency,
followed by treatment with either 4uL of PBS (basal conditions) or 4uL of
cytomix (proinflammatory conditions) and left to incubate in a cell incubator for
5hr (37°C, 5% CO2). Following incubation, the solution was siphoned, and all
cells were fixed in 250uL of ice-cold 4% paraformaldehyde.
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The fixed cells were stained following a similar immunostaining protocol
as outlined in the XperT-permeability section, with minor changes in the volume
of solutions with respect to the larger wells. The primary antibody used was
pFAK 397 rabbit, SAB4504181, following the same ratios as outlined previously.
Following the last PBS wash after immunostaining, the coverslips containing the
fixed and stained cells were transferred onto glass slides containing antifade
mounting medium and sealed. The slides were stored covered at -20°C until
imaged. The samples were imaged using confocal microscopy (Leica TCS SP8)
as Z-stacks.

2.4.2 Quantification of total pFAK abundance and differential pFAK
particulate sizes
Initial analysis of the raw images acquired from confocal microscopy was
performed using the LAS-X proprietary software associated with the Leica TCS
SP8 microscope. The optimal plane was selected when scrolling through the Zstacks per image, with the selection criteria focusing on the pFAK signal at the
basal layer of the cell. Once selected, the snapshot images at the basal plane were
exported to the ImageJ software for pFAK particle analysis.
In ImageJ, exported images were split to extract the red channel,
indicative of the pFAK signal. The red channel image was converted to binary to
reduce the background signal and the remaining particles analyzed according to
size (Figure 2-4). The size selection criteria were as follows: pixels from 0-1
(background or nonselective antibody staining), 2-10 (small), 11-50 (moderate),
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51-100 (large), 101-infinity (background or nonselective antibody staining;
NOTE: 1 pixel= 0.566μm; Figure 2-4). These subsequent results for the small,
moderate, and large pixel categories per image were averaged within the specific
treatment groups and graphed to allow comparison between groups (Figure 2-4).
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Figure 2-4. An example of the pFAK quantification methodology (NOTE: 1 pixel=
0.566μm).
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2.5 Assessment of PMVEC barrier function post-inhibitors
2.5.1 Assessing the impact of PF-573228 (PF-228) on barrier
permeability
To assess the role of FAK activity in local leak under basal and
proinflammatory conditions, WT and Timp3-/- PMVEC were treated with 5, 10,
and 25µM PF-228 (Sigma, cat#324878), a synthetic FAK inhibitor that inhibits
FAK phosphorylation at Tyr397 (concentrations were based on established
literature; Cabrita et al. 2011; Lederer et al. 2018). For these studies, PF-228 or an
equal volume of DMSO (vehicle control for PF-228) was added to PMVEC for
16hr. After 16hr, WT and Timp3-/- PMVEC were stimulated with PBS or cytomix
(30ng/mL) for 5hr and local leak was assessed with using the protocol described
above for the XPerT-permeability assay.

2.5.2 Assessing the impact of BB94 on barrier permeability
To examine the role of metalloproteinases in local leak under basal and
proinflammatory conditions, WT and Timp3-/- PMVEC were treated with 10 and
25µM BB94 (Batimastat, Calbiochem, cat#196440), a synthetic global
metalloproteinase inhibitor, and local leak was examined as above. For these
studies, BB94 or an equal volume of DMSO (vehicle control for BB94) was
added to PMVEC for 16hr. After 16hr, WT and Timp3-/- PMVEC were stimulated
with PBS or cytomix (30ng/mL) for 5hr and local leak was assessed with using
the protocol described above for the XPerT-permeability assay.
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2.6 Statistical Analysis
Depending on the number of variables, differences between groups were
assessed using a paired t-test (one-tailed or two-tailed), a one-way ANOVA with
a Dunnett post hoc test (one independent variable), or a two-way ANOVA with a
Bonferroni post hoc test (two independent variables) using GraphPad Prism 5.
The significance threshold was set at an α of 0.05.
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Chapter 3

3

Results

3.1 Localized paracellular avidin leak in PMVEC
To visualize and assess the localized disruption of inter-PMVEC junctions
and PMVEC-ECM interactions, the use of the novel XperT-permeability assay
and immunofluorescent microscopy was implemented. The XperT-permeability
assay was previously used in our lab to assess VE-cadherin disruption in human
PMVEC under basal vs. proinflammatory conditions. To translate this method
into the mouse model, the assay was optimized for murine WT and Timp3-/PMVEC, under basal vs. cytomix conditions. The cells were cultured on
biotinylated gelatin containing biotin, and the resultant interaction of the
fluorescent avidin which leaked between adjacent PMVEC and bound to subcellular biotin was visualized. The number of total avidin-leak regions per field
was quantified, and we measured the perpendicular distance of avidin diffusion
from the PMVEC borders (as identified by VE-cadherin-staining) beneath the
cells. The studies revealed that trans-PMVEC avidin leak was paracellular, rather
than transcellular, and associated with sites of VE-cadherin disruption (Figure 31A). Additionally, the results indicated a significant increase in the number of
avidin regions in Timp3-/- PMVEC vs. WT PMVEC, under proinflammatory
conditions (Figure 3-1B). Furthermore, there were significant differences in
avidin diffusion distance in WT PMVEC vs. Timp3-/- PMVEC, under basal
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conditions- this trend, while not statistically significant, was reflected in the
cytomix cohorts. (Figure 3-1D).

3.1.1 Timp3-/- PMVEC exhibited enhanced number of avidin regions
under proinflammatory conditions vs. Timp3-/- PMVEC under
basal conditions
When analyzing the visual data as presented by immunofluorescent
imaging, Timp3-/- PMVEC appeared to exhibit increased avidin leak under basal
conditions vs. WT PMVEC under basal conditions and appeared enhanced in the
PMVEC cytomix cohorts (Figure 3-1A). While quantification of the total number
of leak regions revealed no significant differences in total number of leak regions
under PBS-treatment between PMVEC genotypes, the results revealed a trend
towards a greater number of leak regions in Timp3-/- PMVEC vs. WT PMVEC
(Figure 3-1B). Furthermore, Timp3-/- PMVEC demonstrated significant
enhancement in leak regions under cytomix-stimulation vs. PBS-treated Timp3-/PMVEC (Figure 3-1B). However, there was no significant difference in total
number of leak regions between PBS-treated WT PMVEC vs. WT PMVEC under
cytomix-stimulation, though there was a general trend towards a great number of
leak regions in the cytomix-stimulated WT PMVEC vs. PBS-treated WT PMVEC
(Figure 3-1B).
These trends were reflected following quantification of total leak area,
though not statistically significant (Figure 3-1C).
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3.1.2 Timp3-/- PMVEC exhibited longer avidin diffusion lengths vs.
WTPMVEC, under basal conditions
Timp3-/- PMVEC appeared to exhibit greater total avidin fluorescence at
basal conditions vs. WT PMVEC under basal conditions (Figure 3-1A). While
quantification of the avidin diffusion distance beneath the PMVEC from points of
VE-cadherin disruption at PMVEC margins did not reveal a significant difference
between cytomix-stimulated WT PMVEC vs. PBS-treated WT PMVEC, the
results indicated significantly greater diffusion in Timp3-/- PMVEC vs. WT
PMVEC, under PBS-treatment (Figure 3-1D). While this difference in diffusion
lengths was present between PMVEC genotypes in cytomix-stimulated cohorts,
the results were not statistically significant (Figure 3-1D).
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Figure 3-1. Localized protein leak in WT vs. Timp3-/- murine PMVEC. (A) XperT
immunofluorescent staining of WT and Timp3-/- PMVEC treated with PBS (basal) or
stimulated with cytomix (proinflammatory) for 5hr indicated greater avidin leak (green)
in WT PMVEC following cytomix stimulation vs. PBS. Further, Timp3-/- PMVEC
appeared to have greater overall avidin leak vs. WT PMVEC under basal and septic
conditions. Scale bar= 40μm. (B) The total number of avidin leak regions was
significantly greater in cytomix-stimulated Timp3-/- PMVEC vs. WT PMVEC. *p<0.05
vs. cytomix-treated WT PMVEC, two-way ANOVA with Bonferroni post hoc test, n=3.
(C) Quantification of total leak area revealed no significant differences between PMVEC
genotypes or between treatment groups. n=3. (D) The diffusion distance of avidin below
PBS-treated PMVEC was significantly greater in Timp3-/- PMVEC vs. WT PMVEC.
*p<0.05 vs. PBS-treated WT PMVEC, two-way ANOVA with Bonferroni post hoc test,
n=3.

59

3.2 Basal adhesion of WT vs. Timp3-/- PMVEC to gelatin
Previous studies have indicated that mice lacking TIMP3 demonstrated an
increased basal permeability compared to WT mice, which was also reflected at
the cellular level 74. As such, WT and Timp3-/- PMVEC were seeded on a gelatincoated membrane to assess potential differences in cell-matrix adhesion between
PMVEC genotypes as a contributing factor for the enhanced basal permeability
observed. Gelatin was used based on previous studies having established the
adequacy of a gelatin matrix coating for PMVEC adhesion and culture 35.

3.2.1 WT PMVEC and Timp3-/- PMVEC demonstrated no significant
differences in adhesion to gelatin
Analysis of PMVEC adhesion on gelatin revealed no significant
differences between WT vs. Timp3-/- PMVEC. Multiple incubation timepoints
were tested (6hr and 16hr), and both cell types were seeded at 30k and 60k cells/
well (Figure 3-2A, Figure 3-2B). While there seemed to be a possibility of lower
cellular adhesion in Timp3-/- PMVEC vs. WT PMVEC when incubated for 6hr
and 16hr, these results were not statistically significant.
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Figure 3-2. Percentage cellular adhesion of PMVEC to gelatin under basal
conditions. (A) WT and Timp3-/- murine PMVEC were seeded at 60k cells/ well and
incubated for (A) 6hr or (B) 16hr before washing and acquiring total cellular
fluorescence, revealing no significant differences in cellular adhesion between PMVEC
cell types. n=3.
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3.3 Basal adhesion of WT vs. Timp3-/- PMVEC to ECM
proteins
While the adhesion assays revealed no significant basal differences in WT
and Timp3-/- PMVEC adhesion to both gelatin-coated and bare tissue-culture
treated wells, this begged the questions of 1) whether the differences were
maintained when the cells were grown on physiologically-relevant components of
the ECM, 2) whether there were differential interactions of PMVEC depending on
the underlying ECM protein, and 3) whether there was a dose-dependent
interaction of PMVEC to different concentrations of ECM proteins.
As such, a commercial ECM adhesion assay was used to assess the
average percent adhesion of WT and Timp3-/- PMVEC to four common ECM
proteins (collagen I, fibronectin, laminin, vitronectin) coated at varying doses.
The results revealed that PMVEC adhesion between PMVEC genotypes was
comparable per ECM protein (Figure 3-3) However, both PMVEC types
demonstrated differential adhesion to the ECM proteins depending on the
underlying substrate and the concentration of the substrate (Figure 3-3).

3.3.1 Both PMVEC demonstrated comparable adhesion to ECM
proteins
When comparing percent adhesion of PMVEC genotypes to ECM
proteins, the data revealed that WT PMVEC had similar levels of overall adhesion
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vs. Timp3-/- PMVEC for each of the respective ECM proteins (Figure 3-3). This
trend was maintained at all concentrations of the ECM proteins (Figure 3-3).

3.3.2 Both PMVEC demonstrated preferential adhesion to fibronectin,
and the lowest adhesion preference for collagen I
When comparing percent adhesion of PMVEC to different ECM proteins,
both cell types demonstrated greater adhesion to fibronectin vs. other ECM
substrates (Figure 3-3A, 3C). Furthermore, WT PMVEC presented with a
concentration-dependent increase in percent adhesion to fibronectin- however,
this trend plateaued at 10ug/mL, the second highest substrate concentrations
(Figure 3-3A). Additionally, Timp3-/- PMVEC paralleled the WT PMVEC trend
by demonstrating highest adhesion with fibronectin vs. other ECM proteins
(Figure 3-3B, 3C, 3D, 3E).
Both PMVEC demonstrated the lowest adhesion to collagen I substrate
(Figure 3-3B). Interestingly, collagen I seemed to have an inhibitory role on
PMVEC adhesion, as indicated by a dose-dependent decrease in PMVEC
adhesion of both cell types as the concentration of collagen I increased (Figure 33B). This decrease seemed to plateau at a concentration of 2.5ug/mL of collagen I
(Figure 3-3B).
Both cell types demonstrated moderate adhesion to laminin and
vitronectin (Figure 3-3D, 3E). The adhesion of both PMVEC was higher for
laminin and vitronectin than collagen I, but lower than fibronectin, particularly
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when comparing PMVEC adhesion to higher concentration of fibronectin vs.
PMVEC adhesion to the respective laminin and vitronectin concentrations (Figure
3-3A). Neither cell types indicated a concentration-dependent relationship to
laminin or vitronectin (Figure 3-3D, 3E).
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Figure 3-3. Cellular adhesion of WT vs. Timp3-/- murine PMVEC to differing
concentrations of ECM proteins (collagen I, fibronectin, laminin, vitronectin). (A)
WT PMVEC seeded on varying concentrations of four common ECM proteins and
incubated for 2hr before washing, staining, and measuring absorbance revealed a dosedependent, highest affinity for fibronectin, and the lowest affinity towards collagen I.
n=3. (B, C, D, E) Cellular adhesion of WT and Timp3-/- PMVEC to individual ECM
proteins revealed similar adhesive affinity to each ECM protein at different
concentrations. n=3.
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3.4 pFAK abundance in PMVEC
pFAK is commonly used to assess the stability of cell-matrix interactions
15,77,78,80,82,93

. However, many of these studies often show contradicting results in

the association between pFAK abundance and cell-matrix interactions, largely due
to variable factors amongst the experiments (i.e. type of stimuli and time points,
cell type, cellular process being assessed). Interestingly, some studies have also
alluded to the regulatory role of the ECM on barrier stability under inflammatory
conditions 83,94,95.
In order to assess PMVEC-matrix interactions under basal and
inflammatory conditions, pFAK content of WT and Timp3-/- PMVEC seeded on
gelatin was assessed, in response to PBS vs. cytomix treatment. Cell culture
monolayers were stained for pFAK via immunocytochemistry and imaged using
confocal microscopy.

3.4.1 WT PMVEC exhibited a lower number of pFAK particulates
under proinflammatory conditions vs. WT PMVEC under basal
conditions
When assessing the impact of a proinflammatory environment on pFAK
abundance in PMVEC, WT PMVEC demonstrated an enhanced pFAK signal
under basal conditions vs. cytomix treatment. This was reflected when comparing
all pFAK particulate sizes, with WT PMVEC under basal conditions having a
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significantly greater number of pFAK particulates per size category (small,
moderate, large), vs. WT PMVEC under cytomix treatment (Figure 3-4A).

3.4.2 Timp3-/- PMVEC exhibited a lower number of pFAK particulates
vs. WT PMVEC, under basal conditions
Timp3-/- PMVEC exhibited a significantly lower number of small and
moderate particulates vs. WT PMVEC, in the PBS-treated groups (Figure 3-4B).
However, there were no significant differences in abundance of respective pFAK
particulates between the PMVEC genotypes following cytomix-stimulation
(Figure 3-4C).
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Figure 3-4. Quantification of pFAK in PMVEC under basal vs. proinflammatory
conditions. (A) Quantification of pFAK particulates categorized by size (small= 2-10
pixels, moderate= 11-50 pixels, large= 51-100 pixels; NOTE: 1 pixel= 0.566μm) in WT
PMVEC indicated significantly higher levels of small and moderate pFAK particulates in
the PBS-treated vs. cytomix-treated cohort. *p<0.05 vs. PBS-treated WT PMVEC
respective to particulate cohort, two-tailed paired t-test, n=3. (B) Quantification of pFAK
particulates categorized by size indicated higher levels of small and moderate pFAK
particulates in PBS-treated WT PMVEC vs. PBS-treated Timp3-/- PMVEC. *p<0.05 vs.
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PBS-treated WT PMVEC respective to particulate cohort, one-tailed paired t-test, n=3.
(C) Quantification of pFAK particulates categorized by size revealed no significant
difference in pFAK particulates between WT PMVEC vs. Timp3-/- PMVEC, under
cytomix stimulation
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3.5 Effect of FAK inhibitor, PF228, on localized avidin leak
To elucidate the role of FAK in cellular processes, FAK inhibitors have
been tested in numerous cell adhesion, migration, and transformation studies.
Multiple cell types (i.e. platelets, mesenchymal stem cells) and various treatment
protocols (i.e. proinflammatory conditions, VEGF stimulation) have been
assessed 96–98. In recent years, there has been an emphasis on the anti-tumorigenic
potential of FAK inhibitors to treat various cancers 99–101. However, few studies
have looked at the relationship of FAK and PMVEC-ECM adhesion in
maintenance of barrier stability, particularly under proinflammatory conditions.
As such, PF228, a commonly used FAK inhibitor, was used to assess the impact
of inhibiting phosphorylation of FAK on WT vs. Timp3-/- PMVEC barrier
integrity, under basal vs. proinflammatory conditions.

3.5.1 PF228 enhanced localized avidin leak in WT PMVEC under
basal and proinflammatory conditions
WT PMVEC were incubated with various concentrations (5µM, 10µM,
and 25µM respectively) of the PF228 inhibitor for 16hr prior to PBS vs. cytomixtreatment. This was followed by the previously outlined XperT-permeability
assay and immunofluorescent protocol. The results indicated that inhibition of
FAK phosphorylation was associated with an increased level of localized avidin
leak in WT PMVEC under cytomix conditions vs. WT PMVEC control (Figure 35A). Quantifications of the number of avidin leak regions supported this observed
trend under proinflammatory conditions, with cytomix-treated WT PMVEC
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demonstrating a significantly increased number of avidin regions at 25μM of
PF228 vs. WT PMVEC control (Figure 3-6B). Furthermore, quantification of
total avidin leak area revealed a significant increase in total avidin leak in WT
PMVEC when exposed to 25μM of PF228 vs. WT PMVEC control, in both PBStreated and cytomix-stimulated cohorts.

3.5.2 PF228 enhanced total avidin leak area in Timp3-/- PMVEC
under proinflammatory conditions
Immunofluorescent imaging revealed enhanced avidin leak in Timp3-/PMVEC in response to PF228 exposure, particularly under proinflammatory
conditions (Figure 3-5B). While there were no significant differences in number
of avidin leak regions in Timp3-/- PMVEC under basal or proinflammatory
conditions (Figure 3-6C, 6D), quantifications of total avidin area revealed that
cytomix-stimulated Timp3-/- PMVEC exposed to 25μM of PF228 demonstrated
enhanced total avidin area vs. cytomix-stimulated Timp3-/- PMVEC vehicle
control (Figure 3-7D). However, there were no significant differences in total
avidin area in the PBS-treated Timp3-/- PMVEC cohort (Figure 3-7C).
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Figure 3-5. Localized avidin leak (green) in WT and Timp3-/- murine PMVEC,
stained for VE-cadherin (red), following incubation with PF-573228 (PF228), a FAK
inhibitor. (A) WT PMVEC demonstrated a dose-dependent increase in avidin leak to
PF228 in the PBS cohort vs. vehicle control. This was further enhanced in the cytomix
cohort vs. PBS n=3. (B) Timp3-/- PMVEC demonstrated increased avidin leak in the PBS
cohort vs. vehicle control and WT PMVEC at respective PF228 concentrations. This was
further enhanced in the cytomix cohort vs. vehicle control and WT PMVEC at respective
PF228 concentrations. n=3.
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Figure 3-6. Quantification of the number of localized avidin leak regions in WT and
Timp3-/- murine PMVEC, following incubation with PF-573228 (PF228), a FAK
inhibitor. (A) FAK inhibition with PF228 had no significant effect on the number of
avidin leak regions in PBS-treated WT PMVEC. n=3. (B) FAK inhibition (PF228 25µM)
enhanced the number of avidin leak regions in cytomix-stimulated WT PMVEC. *p<0.05
vs. other cytomix-stimulated WT PMVEC groups, one-way ANOVA with Dunnett’s post
hoc test, n=3. (C) PF228 had no significant effect on the number of avidin leak regions in
Timp3-/- PMVEC in the PBS-treated cohorts or (D) in the cytomix-stimulated cohorts.
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Figure 3-7. Quantification of localized avidin leak area in WT and Timp3-/- murine
PMVEC, following incubation with PF-573228 (PF228), a FAK inhibitor. (A) WT
PMVEC demonstrated significant enhancement in total avidin leak area when treated
with 25μM of PF228 vs. WT PMVEC control, in the PBS-treated cohorts and (B) in the
cytomix-stimulated cohorts. *p<0.05 vs. WT PMVEC control, one-way ANOVA with
Dunnett’s post hoc test, n=3. (C) Timp3-/- PMVEC demonstrated no significant
enhancement in the number of avidin leak regions in the PBS-treated cohorts. (D) In the
cytomix-stimulated cohorts, Timp3-/- PMVEC demonstrated significant enhancement in
total avidin leak area when treated with 25μM of PF228 vs. Timp3-/- PMVEC control.
*p<0.05 vs. WT PMVEC control, one-way ANOVA with Dunnett’s post hoc test, n=3.
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3.6 Effect of metalloproteinase inhibitor, BB94, on localized
avidin leak
Previous studies from our lab have shown an attenuation of endothelial
leak following broad-spectrum metalloproteinase inhibition, with higher TEER
(lower permeability) in cells treated with the inhibitor vs. control, particularly
under proinflammatory conditions 74. While certain factors, such as VE-cadherin
disruption, have been implicated in metalloproteinase-dependent endothelial leak,
the underlying mechanism, including the effect of metalloproteinases on cellECM interactions and subsequent impact on PMVEC barrier stability is yet to be
elucidated. As such, the use of a broad-spectrum metalloproteinase inhibitor,
BB94, was implemented to assess localized avidin leak in the murine PMVEC
model, under basal vs. proinflammatory conditions.

3.6.1 BB94 attenuated leak in Timp3-/- PMVEC under basal and
proinflammatory conditions
PMVEC were incubated with various concentrations (10μM and 25μM
respectively) of the BB94 inhibitor for 16hr prior to PBS vs. cytomix-treatment.
This was followed by the previously outlined XperT-permeability assay and
immunofluorescent protocol. The results revealed a limited response of WT
PMVEC to the BB94 inhibitor vs. WT PMVEC control, under both basal and
proinflammatory conditions (Figure 3-8A, Figure 3-9). Furthermore, WT PMVEC
demonstrated no significant attenuation in total avidin leak in response to BB94,
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in either the PBS-treated or cytomix-stimulated cohorts (Figure 3-9C, 9D).
Additionally, quantification of the number of localized leak regions revealed no
significant differences between WT and Timp3-/- PMVEC, nor any significant
differences between PBS vs. cytomix-stimulated cohorts (Figure 3-9A, 9B).
However, Timp3-/- PMVEC treated with BB94 appeared to show a
decrease in localized avidin leak in response to BB94 concentrations vs. control
PMVEC, under both basal and proinflammatory conditions (Figure 3-8B).
Quantification of total avidin leak area supported this observation, with Timp3-/PMVEC treated with 25μM of BB94 demonstrating an attenuation in total avidin
area vs. control, in both PBS-treated and cytomix-stimulated Timp3-/- PMVEC
cohorts (Figure 3-9C, 9D).
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Figure 3-8. Localized avidin leak (green) in WT and Timp3-/- murine PMVEC,
stained for VE-cadherin (red), following incubation with BB94, a broad spectrum
MMP inhibitor. (A) WT PMVEC demonstrated limited attenuation in localized avidin
leak in response to BB94 concentrations of 10μM and 25μM, in the PBS vs. cytomix
cohort. n=3. (B) BB94-treated Timp3-/- PMVEC demonstrated attenuation in localized
avidin leak in the PBS cohort vs. vehicle control. This attenuation was especially
enhanced in the cytomix cohort vs. vehicle control. n=3.
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Figure 3-9. Quantification of localized avidin leak area in WT and Timp3-/- murine
PMVEC, following incubation with BB94, a broad spectrum MMP inhibitor. (A) (B)
Quantification of the number of total avidin leak regions revealed no significant
differences between PMVEC genotypes, or between treatment groups. n=3. (C) In the
PBS cohorts, Timp3-/- PMVEC demonstrated significantly enhanced total avidin leak
under control conditions vs. WT PMVEC control. At a 25μM concentration of BB94, the
total leak area was significantly attenuated in Timp3-/- PMVEC vs. the Timp3-/- PMVEC
control group. *p<0.05 vs. WT PMVEC control, #p<0.05 vs. Timp3-/- PMVEC control,
two-way ANOVA with Bonferroni post hoc test, n=3. (D) In the cytomix-treated cohorts,
Timp3-/- PMVEC demonstrated significantly enhanced total avidin leak under control
conditions vs. WT PMVEC control. At both 10μM and 25μM concentrations of BB94,
the total leak area was significantly attenuated in Timp3-/- PMVEC vs. the Timp3-/-
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PMVEC control group. *p<0.05 vs. WT PMVEC control, #p<0.05 vs. Timp3-/- PMVEC
control, two-way ANOVA with Bonferroni post hoc test, n=3.
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Chapter 4

4

Discussion

4.1 Summary of Findings
The pulmonary endothelium is vital in maintaining the homeostatic
function of the lungs by providing a highly regulated barrier for the controlled
movement of macromolecules 102. Dysfunction of the PMVEC barrier, which is
associated with inflammatory pathologies like sepsis, results in an uncontrolled
accumulation of protein-rich edema fluid within the distal airspaces of the lungs,
impeding gas exchange 103. The loss of pulmonary function has a broad effect on
the body and is ultimately associated with multi-organ failure and subsequent
death 9. Thus, understanding the mechanisms that regulate PMVEC barrier
function are critical for developing adequate treatments to target endothelial
dysfunction under proinflammatory conditions in the lungs.
PMVEC barrier function is dependent on interaction between adjacent
PMVEC, as well as interaction between PMVEC and the underlying ECM leading
to the formation of FAC 15,77,78. Further, it has been suggested that loss of cellECM interactions can promote endothelial cell barrier dysfunction 15,77,78.
Previous studies have demonstrated that TIMP3 appears to have the ability to
regulate inter-PMVEC interactions and subsequently, PMVEC barrier function
11,74

. Further, in the developing lung, TIMP3 has been shown to regulate cell-

ECM interactions 75. The underlying mechanism through which TIMP3 regulates
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PMVEC barrier function and whether this mechanism is dependent on PMVECECM interactions is unknown.
In this study, I was able to identify a potential role for TIMP3 in
regulating PMVEC-ECM interactions leading to formation of focal adhesions and
PMVEC barrier stability (Figure 4-1). Specifically, Timp3-/- PMVEC had
significantly decreased pFAK vs. WT PMVEC under basal conditions and this
was associated with increased local leak and leak diffusion beneath Timp3-/PMVEC. Moreover, the increased leak around Timp3-/- PMVEC was rescued by
treatment with BB94 suggesting that TIMP3 regulation of PMVEC-ECM
interaction appeared to be metalloproteinase-dependent. I was also able to
demonstrate that formation of FAC and subsequent FAK activation was required
for PMVEC barrier function. Specifically, inhibition of FAK activity resulted in
local leak around WT PMVEC under basal conditions and significantly
exacerbated cytomix-induced leak. Inhibition of FAK also exacerbated the basal
and septic leak around Timp3-/- PMVEC. Collectively, these findings suggest that
PMVEC dysfunction under proinflammatory conditions may occur via disruptions
in the TIMP3-mediated PMVEC-ECM interactions, and may offer novel
therapeutic approaches to treat endothelial barrier dysfunction in the lungs, as
associated with proinflammatory pathologies (Figure 4-1).
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Figure 4-1. TIMP3 promotes PMVEC barrier function through stabilizing focal
adhesion formation and FAK activation. UPPER PANEL: Under basal conditions,
TIMP3 appears to inhibit metalloproteinases, allowing for adequate integrin-ECM
interactions. This promotes phosphorylation of focal adhesion kinase (FAK) and allows
for assembly of focal adhesion complexes (FAC), which stabilize integrin-ECM
interactions. Adherens junctions are maintained between adjacent PMVEC, and further
stabilized by FAC signaling via F-actin filaments. LOWER PANEL: In the absence of
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TIMP3, metalloproteinase activity is enhanced, allowing for the degradation of the ECM,
integrins, and VE-cadherin. The loss of ECM and integrins leads to disassembly of FAC.
VE-cadherin cleavage leads to loss of adherens junctions. Together, these events lead to a
loss of PMVE-ECM and inter-PMVEC interactions.
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4.2 Contributions of Research to Current Knowledge
4.2.1 TIMP3 regulates local leak around PMVEC
Previous studies demonstrated reduced TEER and enhanced EB albumin
leak across Timp3-/- PMVEC demonstrating greater overall leak 74. To examine
the local leak around individual cells, I utilized the XPerT-permeability assay in
the murine WT and Timp3-/- PMVEC, which also enabled me to assess leak in
relation to VE-cadherin disruption, and assess the potential impact of interaction
of PMVEC with the underlying matrix.
Under basal conditions, the avidin leak diffusion was greater under the
Timp3-/- PMVEC vs. WT PMVEC, which also appeared to have increased VEcadherin disruption. Furthermore, the number of avidin leak regions was greatly
enhanced in Timp3-/- PMVEC exposed to proinflammatory conditions vs. Timp3-/PMVEC under basal conditions.
These results support previous studies that have associated VE-cadherin
disruption with increased levels of leak, due to loss of inter-PMVEC interactions
88

. They also confirm previous finding that have demonstrated enhanced albumin

leak and reduced TEER across Timp3-/- PMVEC vs. WT PMVEC, supporting the
idea that TIMP3 is a crucial component for EC barrier regulation. Furthermore,
the enhanced diffusion distance under basal Timp3-/- PMVEC vs. WT PMVEC,
combined with previous reports of the importance of cell-ECM interactions in
maintaining EC function, alludes to a potential disruption in PMVEC-ECM
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interactions in the absence of TIMP3 26,28,29. Thus, these results suggest that there
were an altered number of localized avidin leak and altered avidin leak diffusion
beneath the cells that had reduced cell-matrix interactions further highlighting the
importance of PMVEC-ECM interactions in supporting PMVEC barrier function.
Overall, these results provide a novel approach for studying barrier
dysfunction through direct visualization and subsequent quantification of
localized avidin leak in the murine PMVEC model, in addition to the previously
established methods of measuring TEER and EB albumin leak. This is especially
useful for visually assessing leak in relation to VE-cadherin disruption or for
future studies looking at other proteins-of-interest in relation to murine PMVEC
barrier integrity.

4.2.2 TIMP3 does not appear to regulate initial PMVEC-ECM
adhesion
TIMP3 has the ability to mediate cell-ECM interaction and there is
evidence that PMVEC-ECM interactions promote PMVEC barrier function 44,104.
Based on this, I began to investigate whether alterations in initial adhesion of WT
vs. Timp3-/- PMVEC were present that may explain the enhanced leak and barrier
dysfunction associated with loss of TIMP3.
Previous studies have shown that TIMP3 can regulate cell-matrix adhesion
through metalloproteinase-dependent processes 11,48,75. For example, suppression
of TIMP3 in cancer cells has been associated with increased metalloproteinase
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expression (i.e. MMP9, ADAM17) reduced cell adhesion and increased cell
migration

105,106

. My data, however, found no significant differences in initial

cellular adhesion between WT and Timp3-/- PMVEC to their underlying substrate.
Furthermore, both WT and Timp3-/- PMVEC demonstrated a similar adhesion
response to each of the commonly used ECM proteins. Collectively, these
findings suggest a limited role for TIMP3 in initial PMVEC cell adhesion and
appears to indicate that TIMP3 does not confer an adhesion preference to specific
matrices.
One potential reason for these observed differences may be the nature of
the cell types being examined. Most studies assessing the role of TIMP3 on
cellular adhesion were looking at highly-proliferative, migratory cells, as opposed
to a quiescent PMVEC monolayer under basal conditions 107–109. Furthermore,
many of these studies specifically implemented cancerous cell lines, which
demonstrate a differential genotype and phenotype as compared healthy PMVEC
110,111

. These variations in study design may explain the differential results of my

cell adhesion studies using a PMVEC monolayer as compared to other studies
using migratory, tumorigenic models.
It is also important to note that my cell adhesion data only suggests that
TIMP3 is not required for the initial adhesion of PMVEC to the underlying ECM.
However, the observed increase in leak diffusion beneath Timp3-/- PMVEC vs.
WT PMVEC, as well as the significant reduction in pFAK within Timp3-/PMVEC vs. WT PMVEC both suggest that TIMP3 has the ability to regulate
PMVEC interaction with the ECM. This is supported by previous studies in
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Timp3-/- mice. Specifically, lungs from mice lacking TIMP3 had increased
metalloproteinase activity leading to enhanced fibronectin degradation 75. This
degradation of fibronectin resulted in decreased epithelial cell-ECM interaction
and a significant reduction in FAK phosphorylation 75.
Initial cell attachment to the ECM is driven by specific integrin-mediated
interactions with the matrix- these start off as single receptor-ligand pairs and
over time, as the monolayer forms, more bonds are initiated to confer greater
adhesive strength. However, interaction of an established monolayer with the
underlying ECM is mediated largely by the presence of metalloproteinases, which
can interfere with the established cell-ECM interactions- by regulating
metalloproteinase activity, TIMPs are particularly important to maintain basal
conditions in an established endothelial monolayer 53. Thus, while not examined
within the context of my study, this may be one explanation for why TIMP3 does
not appear to have a role in regulating the initial PMVEC-ECM adhesion but does
appear to be a critical mediator of PMVEC-ECM interaction in the PMVEC
barrier.

4.2.3 FAK activation promotes PMVEC barrier function and is
regulated by TIMP3
FAK has been studied extensively in proliferating and migrating cells,
with substantial implications for cancer research 112. However, there is limited
research on the role of focal adhesions in relation to endothelial barrier function.
Furthermore, the data currently present regarding focal adhesions and EC is often
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opposing 15,77,78,81,82,84. For instance, one study showed that thrombin-stimulation
enhanced FAK phosphorylation in HUVEC, while another study revealed that
thrombin exposure reduced FAK expression in human pulmonary arterial EC 15,81.
Interestingly, WT PMVEC exposed to proinflammatory stimuli were
found to have reduced levels of pFAK vs. WT PMVEC under basal conditions.
Additionally, inhibition of FAK activity in WT PMVEC resulted in a significant
increase in localized avidin leak under both basal and proinflammatory
conditions. Collectively, these two lines of evidence suggest that FAK activation
is crucial in maintaining adequate barrier function in PMVEC and support
previous work in human pulmonary arterial EC.
My data in combination with other studies also suggests that the role of
FAK in barrier function may be dependent on the specific EC being studied, the
stimulation used, and the timespan examined. For example, FAK may promote
barrier function in microvascular EC, such as PMVEC, but have a different role in
macrovascular EC, such as HUVEC. In fact, previous work has demonstrated
differential responses to albumin leak between macrovessels (i.e. HUVECs) and
microvessels (i.e. human pulmonary MVEC), which is not surprising given the
heterogeneity between the vessels of vasculature 3–5,113.
Timp3-/- PMVEC were also found to have significantly reduced levels of
pFAK vs. WT PMVEC under basal conditions, and were found to have enhanced
avidin leak in response to FAK inhibition when exposed to proinflammatory
conditions. This supports previous work demonstrating that a loss of TIMP3 leads
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to reduced pFAK and highlights the potential role for TIMP3 in regulating
PMVEC-ECM interaction 75. It also emphasizes the importance of both TIMP3
and FAK in maintaining a functioning PMVEC barrier, and suggests that
reduction of both TIMP3 and pFAK, as associated with inflammation, is highly
detrimental to PMVEC barrier function (Figure 4-1).
In face of opposing studies showing differential pFAK response to a
proinflammatory stimuli, my results provide a more concrete understanding of the
effect of inflammation on pFAK abundance in PMVEC, the subsequent
importance of pFAK in maintaining the PMVEC barrier, and the potential role of
TIMP3 regulating pFAK. Furthermore, based on our previous understanding of
the importance of pFAK in maintaining functional cell-matrix interactions and
consequently a functional barrier, this response to an inflammatory environment
suggests a potential link between reduced focal adhesion signaling and enhanced
barrier dysfunction.

4.2.4 Metalloproteinase-dependent role of TIMP3 on PMVEC barrier
stability
Metalloproteinases have previously been found to mediate EC barrier
function. For example, both MMP2 and -9 have been associated with increased
PMVEC permeability via degradation of matrix proteins, while ADAM15 has
been implicated in altering EC barrier permeability by disrupting adherens
junctions and promoting monocyte transmigration 11,25. Moreover, the increased
leak observed in the absence of TIMP3 is thought to be due, at least in part, to
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increased metalloproteinase activity as treatment of Timp3-/- PMVEC with a
synthetic metalloproteinase inhibitor (GM6001) while in culture rescued the
observed decrease in TEER 74.
Previous studies have shown that loss of TIMP3 is associated with
enhanced metalloproteinase activity 11,59. Furthermore, degradation of the ECM
due to metalloproteinase activity is associated with impaired focal adhesion
signaling, which is problematic on multiple fronts. Firstly, loss of focal adhesions
impairs the ability of cells to form adequate integrin-ECM interactions,
compromising cell-matrix interactions 45,114. Furthermore, focal adhesions have
been shown to interact with and potentially stabilize adherens junctions via
intracellular F-actin signaling 14,115. As such, impaired focal adhesions prevents
stabilization of adherens junctions between adjacent PMVEC, which, with the
addition of enhanced metalloproteinase activity, leads to cleavage of VE-cadherin
and loss of inter-PMVEC junctions 11,14. Additionally, pFAK signaling is further
altered under proinflammatory stimuli 15,46,77.
My findings, in combination with these studies, allude to the potential link
between metalloproteinases, TIMP3, and FAK in regulating PMVEC barrier
function, as Timp3-/- PMVEC had significantly increased leak associated with
significantly reduced pFAK vs. WT PMVEC under both basal and
proinflammatory conditions. Moreover, inhibition of metalloproteinases rescued
the observed leak in Timp3-/- PMVEC under both basal and proinflammatory
conditions. This is potentially due to inhibition of metalloproteinase-dependent
degradation of the matrix and adherens junctions, which stabilizes integrin-ECM
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interactions, allowing for formation of focal adhesions. This in turn supports
intracellular signals that maintain inter-PMVEC junctions and PMVEC-ECM
interactions (Figure 4-1).
These results indicate a potential link between the action of TIMP3 on
PMVEC barrier function via metalloproteinase-dependent processes, possibly
through downstream actions on FAK. Some studies support the idea that
metalloproteinase inhibition is associated with FAK activation, though no present
data exists for the murine PMVEC model under proinflammatory conditions 85.
As such, these results provide a promising avenue for future studies to assess the
role of metalloproteinase-dependent TIMP3 action on PMVEC barrier function
through FAK regulation.

4.3 Limitations and Future Directions
All experiments were conducted under in vitro conditions, with most
experiments utilizing murine PMVEC grown on gelatin-coated, cell culturetreated plates. While cells were grown under physiologically-relevant conditions
(37°C, 5% CO2) with supplemented DMEM growth medium, the conditions were
not completely representative of an in vivo vascular environment. Under
physiological conditions, the endothelium is exposed to various haemodynamic
stimuli (i.e. shear stress, vasoactive compounds), which stimulates the EC and
surrounding cytoskeleton to constantly reshape the EC monolayer in response to
in vivo signals 40. Future studies should incorporate the use of a model with shear
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stress to better assess the response of the PMVEC monolayer under physiological
conditions.
In addition, most of my studies, with the exception of the cell adhesion
assay, were conducted using gelatin as the underlying matrix. While our lab has
historically utilized gelatin as a substrate for human and mouse PMVEC, gelatin
may not be considered physiologically relevant and it may be beneficial to use
matrices that are more representative of in vivo conditions 74,88,116. Specifically,
repeating the studies utilizing fibronectin could be beneficial as that is the matrix
substrate that PMVEC appeared to have the highest affinity in my cell adhesion
assays. It is important to note, however, that my cell adhesion studies with gelatin
showed similar results to those obtained with other ECM proteins. Moreover, I
also performed pilot studies examining pFAK in PMVEC grown on fibronectin
with very similar results to those obtained from PMVEC grown on gelatin.
When studying the role of FA, a potential pitfall of my experiments is that
only FAK, specifically pFAK, was used to assess focal adhesion signaling in the
PMVEC. While pFAK has been shown to be a major component of focal
adhesions through recruitment of various proteins to form FAC and promote
further downstream effects, future studies should assess other upstream and
downstream proteins that may be involved in the focal adhesion pathway (i.e.
integrins, paxillin, and vinculin) 14,45,117. This may help better understand the
effect of differential pFAK expression in PMVEC on downstream signaling
pathways and help elucidate a potential mechanism for the link between cellECM interactions, FA, and PMVEC barrier function. Furthermore, future studies
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should use western blot analysis to look at protein levels of total FAK in relation
to pFAK in PMVEC to better understand the mechanism that leads to altered
pFAK abundance in PMVEC, in relation to loss of TIMP3, and under cytomix
stimulation. Further, while my studies using a FAK inhibitor strongly suggest that
FAK is critical to PMVEC barrier function, future studies could examine the
effects of overexpressing pFAK in PMVEC, via FAK gene amplification, to
assess a potential means of rescuing enhanced PMVEC permeability. This could
be applied to other barrier studies using TEER or EB albumin leak to assess the
replicability of my results in other methods of measuring PMVEC barrier
integrity.
While my experiments have revealed a link between TIMP3, FA, and
PMVEC barrier function, the underlying mechanism remains unclear. The
metalloproteinase inhibitor data suggests that the role of TIMP3 in regulating FA
stability and subsequently, PMVEC monolayer integrity, is dependent on
metalloproteinase inhibition. However, future studies need to measure pFAK
content in PMVEC treated with BB94 to assess whether there is a change in
pFAK abundance following metalloproteinase inhibition. Furthermore, it will also
be important to determine how TIMP3 is linked to FAK activation and focal
adhesion formation, which could be through metalloproteinase-dependent
processes that enhance degradation of the underlying ECM or through cleavage of
cell surface receptors, such as integrins 11,53. To address this, future studies could
utilize a technique such as terminal amine isotopic labelling of substrates (TAILS)
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to examine protein degradation in WT and Timp3-/- PMVEC under basal and
proinflammatory conditions.
Finally, while some of my experiments revealed striking trends, they did
not reach the level of significance. For example, while quantification of total leak
area showed that Timp3-/- PMVEC had greater under cytomix stimulation vs.
under PBS treatment, this trend was not statistically significant (Figure 3-1).
Similarly, quantification of leak regions following FAK inhibition (i.e. addition of
PF228 at 25uM) showed increased leak in both WT and Timp3-/- PMVEC
cohorts- however, these results were not statistically significant. This was likely
due to a low n-value (n=3) combined with high variability due to the use of two
biologically different murine PMVEC isolations. The use of different PMVEC
isolations is absolutely critical as it demonstrates that the observed differences
between WT and Timp3-/- PMVEC are not due to isolation effects. To address
this, these studies should be repeated to increase the n-value. Furthermore, my
studies were performed in mouse PMVEC. It would be beneficial to repeat all
conducted and proposed experiments with human PMVEC to assess the clinical
relevance of my findings.

4.4 Summary and Conclusions
Collectively, my data indicates that TIMP3 may regulate PMVEC barrier
function through metalloproteinase-dependent regulation of PMVEC-ECM
interaction and focal adhesion formation. Moreover, PMVEC barrier dysfunction
under inflammatory conditions is associated with disrupted cell-matrix
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interactions and the loss of TIMP3 may be a contributing factor in this process.
Overall, this study enhances our understanding of PMVEC barrier stability by
providing an insight of the physiological processes that regulate endothelial
barrier function, and how these may be affected under pathological conditions.
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